

A5

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
WO 01/92501 A1(51) International Patent Classification<sup>7</sup>: C12N 9/12, C12Q 1/68, 1/48, C12P 19/34, C07K 14/00, 1/00

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/17492

(22) International Filing Date: 29 May 2001 (29.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/207,567 26 May 2000 (26.05.2000) US  
09/640,958 16 August 2000 (16.08.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): MJ BIOWORKS, INC. [US/US]; 384 Oyster Point Blvd., #8, South San Francisco, CA 94080 (US).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (for US only): WANG, Yan [CN/US]; 1370 11th Avenue, #6, San Francisco, CA 94122 (US).

(74) Agents: LOCKYER, Jean, M. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eight Floor, San Francisco, CA 94111 (US).

WO 01/92501 A1

(54) Title: IMPROVED NUCLEIC ACID MODIFYING ENZYMES

(57) Abstract: This invention provides for an improved generation of novel nucleic acid modifying enzymes. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.

5

## IMPROVED NUCLEIC ACID MODIFYING ENZYMES

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority of U.S. Provisional Application 10 Serial No. 60/207,567 filed May 26, 2000, and claims priority to U.S. Application No. 09/640,958, filed August 16, 2000. Each application is herein incorporated by reference.

### FIELD OF THE INVENTION

This invention provides for an improved generation of novel nucleic acid 15 modifying enzymes. The improvement is the joining of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.

### BACKGROUND OF THE INVENTION

20 The efficiency of a nucleic acid modifying enzyme, *i.e.*, the amount of modified product generated by the enzyme per binding event, can be enhanced by increasing the stability of the modifying enzyme/nucleic acid complex. The prior art has suggested that attachment of a high probability binding site, *e.g.*, a positively charged binding tail, to a nucleic acid modifying enzyme can increase the frequency with which the modifying enzyme 25 interacts with the nucleic acid (*see, e.g.*, U.S. Patent No. 5, 474,911). The present invention now provides novel modifying enzymes in which the double-stranded conformation of the nucleic acid is stabilized and the efficiency of the enzyme increased by joining a sequence-non-specific double-stranded nucleic acid binding domain to the enzyme, or its catalytic domain. The modifying proteins that are processive in nature exhibit increased processivity 30 when joined to a binding domain compared to the enzyme alone. Moreover, both processive and non-processive modifying enzymes exhibit increased efficiency at higher temperatures when joined to a typical binding domain described herein.

In one aspect, the invention provides fusion polymerases that provide an enhanced ability to perform long PCR, *i.e.*, amplification of sequences of 5 kb or greater in length. Polymerase mixture to perform long PCR are known in the art. One difficulty with such mixtures is that long extension times are required for optimal yields of the expected products. Conventional recommendations are to allow extension times of 1 minute per kb. For a 10 kb product and using 40 cycles of amplification, the PCR requires approximately seven hours. Described herein are modified polymerase enzymes that exhibit an enhanced ability to perform long PCR compared to those polymerases and/or polymerase mixtures currently available. These modified enzymes, *e.g.*, Pfu-Sso7d, incorporate a polymerase with error-correcting activity and a sequence-nonspecific double-stranded DNA-binding domain, and therefore provide the capability of PCR amplifying DNA larger than 5 kb without need to resort to polymerase mixtures. In addition, such modified enzymes can efficiently amplify a given fragment using shorter extension times than are required by conventional polymerase mixtures. Thus, use of the hybrid polymerases described herein instead of the conventional mixtures can greatly decrease the reaction time required to amplify large fragments, *e.g.* from about seven hours to about two hours.

## SUMMARY OF THE INVENTION

The present invention provides a protein consisting of at least two heterologous domains wherein a first domain that is a sequence-non-specific double-stranded nucleic acid binding domain is joined to a second domain that is a catalytic nucleic acid modifying domain having a processive nature, where the presence of the sequence-non-specific double-stranded nucleic acid binding domain enhances the processive nature of the nucleic acid modifying domain compared to an identical protein not having a sequence-non-specific nucleic acid binding domain joined thereto. In one aspect of the invention, the nucleic acid modifying domain can have a polymerase activity, which can be thermally stable, *e.g.*, a *Thermus* polymerase domain. In alternative embodiments, the catalytic domain is an RNA polymerase, a reverse transcriptase, a methylase, a 3' or 5' exonuclease, a gyrase, or a topoisomerase.

In a particular embodiment, a sequence-non-specific nucleic acid binding domain of the protein can specifically bind to polyclonal antibodies generated against Sac7d or Sso7d. Alternatively, the sequence-non-specific nucleic acid binding domain can contain a 50 amino acid subsequence that has 50% amino acid similarity to Sso7d. The nucleic acid binding domain can also be Sso7d.

In another embodiment, a protein of the invention contains a sequence-non-specific double-stranded nucleic acid binding domain that specifically binds to polyclonal antibodies generated against a PCNA homolog of *Pyrococcus furiosus*, or can be a PCNA homolog of *Pyrococcus furiosus*.

5 The invention also provides a protein consisting of at least two heterologous domains, wherein a first domain that is a sequence-non-specific double-stranded nucleic acid binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain, where the presence of the sequence-non-specific nucleic-acid binding domain stabilizes the double-stranded conformation of a nucleic acid by at least 1°C compared to an 10 identical protein not having a sequence-non-specific nucleic acid binding domain joined thereto. The nucleic acid modifying domain of such a protein can have polymerase activity, which can be thermally stable. The nucleic-acid-modifying domain can also have RNA polymerase, reverse transcriptase, methylase, 3' or 5' exonuclease, gyrase, or topoisomerase activity.

15 In further embodiments, the sequence-non-specific nucleic-acid-binding domain can specifically bind to polyclonal antibodies generated against either Sac7d or Sso7d, frequently Sso7d, or contains a 50 amino acid subsequence containing 50% or 75% amino acid similarity to Sso7d. Often, the sequence-non-specific nucleic-acid-binding domain is Sso7d.

20 Proteins of the invention include a protein wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against the PCNA homolog of *Pyrococcus furiosus*; often the binding domain is the PCNA homolog of *Pyrococcus furiosus*.

25 In another aspect, the invention provides methods of modifying nucleic acids using the proteins. One embodiment is a method of modifying a nucleic acid in an aqueous solution by: (i) contacting the nucleic acid with a protein comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain having a processive nature, where the sequence-non-specific nucleic-acid-binding 30 domain: a. binds to double-stranded nucleic acid, and b. enhances the processivity of the enzyme compared to an identical enzyme not having the sequence non-specific nucleic-acid-binding domain fused to it, and wherein the solution is at a temperature and of a composition that permits the binding domain to bind to the nucleic acid and the enzyme to function in a

catalytic manner; and (ii) permitting the catalytic domain to modify the nucleic acid in the solution.

In another aspect, the invention provides a method of modifying a nucleic acid by: (i) contacting the nucleic acid with an aqueous solution containing a protein having at least two heterologous domains, wherein a first domain that is a sequence-non-specific double-stranded nucleic-acid-binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain, where the presence of the sequence-non-specific nucleic-acid-binding domain stabilizes the formation of a double-stranded nucleic acid compared to an otherwise identical protein not having the sequence-non-specific nucleic-acid-binding domain joined to it; and wherein the solution is at a temperature and of a composition that permits the binding domain to bind to the nucleic acid and the enzyme to function in a catalytic manner; and (ii) permitting the catalytic domain to modify the nucleic acid in the solution. The methods of modifying a nucleic acid can employ any of the protein embodiments described herein.

In further aspects, the invention provides a method of amplifying a 5kb or longer subsequence of a target nucleic acid in an aqueous solution using a polymerase chain reaction, the method comprising: (i) contacting the target nucleic acid with a protein comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a polymerase domain with error-correcting activity, where the sequence non-specific nucleic-acid-binding domain: (a) binds to double-stranded nucleic acid, and (b) enhances the processivity of the polymerase compared to an identical polymerase not having the sequence non-specific nucleic-acid-binding domain fused to it, and, wherein the solution is of a composition that permits the binding domain to bind to the target nucleic acid and the polymerase domain to extend a primer that is hybridized to the target nucleic acid sequence to a length of 5 kb or longer; (ii) incubating the solution using a polymerase chain reaction temperature profile that amplifies the 5 kb or longer subsequence. In one embodiment of the method, the nucleic-acid-modifying domain has thermally stable polymerase activity. Often, the nucleic-acid modifying domain comprises a *Pyrococcus* polymerase domain. In other embodiments of the method, the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either Sac7d or Sso7d, contains a 50 amino acid subsequence containing 50% amino acid similarity to Sso7D, or specifically binds to polyclonal antibodies generated against Sso7d. In another embodiment, the sequence-non-specific nucleic-acid-binding domain is Sso7d.

In another aspect, the invention provides a method of amplifying a subsequence of a target nucleic acid in an aqueous solution using a polymerase chain reaction, the method comprising (i) contacting the target nucleic acid with a protein comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a polymerase domain with error-correcting activity, where the sequence non-specific nucleic-acid-binding domain: (a) binds to double-stranded nucleic acid, and (b) enhances the processivity of the polymerase compared to an identical polymerase not having the sequence non-specific nucleic-acid-binding domain fused to it, and wherein the solution comprises  $10^5$  or fewer 5 copies/ml of the target nucleic acid and is of a composition that permits the binding domain to bind to the target nucleic acid and the polymerase domain to extend a primer that is hybridized to the target nucleic acid sequence; (ii) incubating the solution using a polymerase chain reaction temperature profile that amplifies the subsequence. In one embodiment of the method, the nucleic-acid-modifying domain has thermally stable polymerase activity. Often, 10 the nucleic-acid modifying domain comprises a *Pyrococcus* polymerase domain. In other embodiments of the method, the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either *Sac7d* or *Sso7d*, contains a 15 50 amino acid subsequence containing 50% amino acid similarity to *Sso7D*, or specifically binds to polyclonal antibodies generated against *Sso7d*. In another embodiment, the 20 sequence-non-specific nucleic-acid-binding domain is *Sso7d*.

## DEFINITIONS

“Archaeal small basic DNA-binding protein” refers to protein of between 50-75 amino acids having either 50% homology to a natural Archaeal small basic DNA-binding 25 protein such as *Sso-7d* from *Sulfolobus sulfataricus* or binds to antibodies generated against a native Archaeal small basic DNA-binding protein.

“Catalytic nucleic-acid-modifying domains having a processive nature” refers to a protein sequence or subsequence that performs as an enzyme having the ability to slide along the length of a nucleic acid molecule and chemically alter its structure repeatedly. A 30 catalytic domain can include an entire enzyme, a subsequence thereof, or can include additional amino acid sequences that are not attached to the enzyme or subsequence as found in nature.

“Domain” refers to a unit of a protein or protein complex, comprising a polypeptide subsequence, a complete polypeptide sequence, or a plurality of polypeptide

sequences where that unit has a defined function. The function is understood to be broadly defined and can be ligand binding, catalytic activity or can have a stabilizing effect on the structure of the protein.

5 "Efficiency" in the context of a nucleic acid modifying enzyme of this invention refers to the ability of the enzyme to perform its catalytic function under specific reaction conditions. Typically, "efficiency" as defined herein is indicated by the amount of modified bases generated by the modifying enzyme per binding to a nucleic acid.

"Enhances" in the context of an enzyme refers to improving the activity of the enzyme, *i.e.*, increasing the amount of product per unit enzyme per unit time.

10 "Fused" refers to linkage by covalent bonding.

"Heterologous", when used with reference to portions of a protein, indicates that the protein comprises two or more domains that are not found in the same relationship to each other in nature. Such a protein, *e.g.*, a fusion protein, contains two or more domains from unrelated proteins arranged to make a new functional protein.

15 "Join" refers to any method known in the art for functionally connecting protein domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding; hydrogen bonding; electrostatic bonding; and conformational bonding, *e.g.*, antibody-antigen, and biotin-avidin associations.

20 "Methylase" refers to an enzyme that can modify a nucleic acid by the addition of a methyl group to a nucleotide.

"Nuclease" refers to an enzyme capable of cleaving the phosphodiester bonds between nucleotide subunits of nucleic acids.

25 "Nucleic-acid-modifying enzyme" refers to an enzyme that covalently alters a nucleic acid.

"Polymerase" refers to an enzyme that performs template-directed synthesis of polynucleotides.

30 "Error-correcting activity" of a polymerase or polymerase domain refers to the 3' to 5' exonuclease proofreading activity of a template-specific nucleic acid polymerase whereby nucleotides that do not form Watson-Crick base pairs with the template are removed from the 3' end of an oligonucleotide, *i.e.*, a strand being synthesized from a template, in a sequential manner. Examples of polymerases that have error-correcting activity include polymerases from *Pryococcus furiosus*, *Thermococcus litoralis*, and *Thermotoga maritima*.

“Processivity” refers to the ability of a nucleic acid modifying enzyme to remain attached to the template or substrate and perform multiple modification reactions. Typically “processivity” refers to the ability to modify relatively long tracts of nucleic acid.

“Restriction Endonuclease” refers to any of a group of enzymes, produced by 5 bacteria, that cleave molecules of DNA internally at specific base sequences.

“Sequence-non-specific nucleic-acid-binding domain” refers to a protein domain which binds with significant affinity to a nucleic acid, for which there is no known nucleic acid which binds to the protein domain with more than 100-fold more affinity than another nucleic acid with the same nucleotide composition but a different nucleotide 10 sequence.

“Thermally stable polymerase” as used herein refers to any enzyme that catalyzes polynucleotide synthesis by addition of nucleotide units to a nucleotide chain using DNA or RNA as a template and has an optimal activity at a temperature above 45°C.

“*Thermus* polymerase” refers to a family A DNA polymerase isolated from 15 any *Thermus* species, including without limitation *Thermus aquaticus*, *Thermus brockianus*, and *Thermus thermophilus*; any recombinant enzymes deriving from *Thermus* species, and any functional derivatives thereof, whether derived by genetic modification or chemical modification or other methods known in the art.

“Polymerase chain reaction” or “PCR” refers to a method whereby a specific 20 segment or subsequence of a target double-stranded DNA, is amplified in a geometric progression. PCR is well known to those of skill in the art; *see, e.g.*, U.S. Patents 4,683,195 and 4,683,202; and *PCR Protocols: A Guide to Methods and Applications*, Innis *et al.*, eds, 1990.

“Long PCR” refers to the amplification of a DNA fragment of 5 kb or longer 25 in length. Long PCR is typically performed using specially-adapted polymerases or polymerase mixtures (*see, e.g.*, U.S. Patent Nos. 5,436,149 and 5,512,462) that are distinct from the polymerases conventionally used to amplify shorter products.

A “primer” refers to a polynucleotide sequence that hybridizes to a sequence on a target nucleic acid and serves as a point of initiation of nucleic acid synthesis. Primers 30 can be of a variety of lengths and are often less than 50 nucleotides in length, for example 12-25 nucleotides, in length. The length and sequences of primers for use in PCR can be designed based on principles known to those of skill in the art, *see, e.g.*, Innis *et al.*, *supra*.

A “temperature profile” refers to the temperature and lengths of time of the denaturation, annealing and/or extension steps of a PCR reaction. A temperature profile for a

PCR reaction typically consists of 10 to 60 repetitions of similar or identical shorter temperature profiles; each of these shorter profiles typically define a two step or three-step PCR reaction. Selection of a "temperature profile" is based on various considerations known to those of skill in the art, *see, e.g.*, Innis *et al.*, *supra*. In a long PCR reaction as described 5 herein, the extension time required to obtain an amplification product of 5 kb or greater in length is reduced compared to conventional polymerase mixtures.

PCR "sensitivity" refers to the ability to amplify a target nucleic acid that is present in low copy number. "Low copy number" refers to  $10^5$ , often  $10^4$ ,  $10^3$ ,  $10^2$ , or fewer, copies of the target sequence in the nucleic acid sample to be amplified.

10 A "template" refers to a double stranded polynucleotide sequence that comprises the polynucleotide to be amplified, flanked by primer hybridization sites. Thus, a "target template" comprises the target polynucleotide sequence flanked by hybridization sites for a 5' primer and a 3' primer.

15

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1a-c shows the results of PCR amplification reactions performed using primers of different lengths to compare the efficiency of Sso7d-modified polymerase with the unmodified full-length polymerase.

20 Figure 2 shows the results of a PCR amplification reaction using a 12 nt forward primer to evaluate the PCR products generated using Sac7d- $\Delta$ Taq compared to Taq.

Figure 3 shows the results of PCR amplification reactions that demonstrate that Pfu-Sso7d is more efficient than DyNAzyme EXT in long PCR.

25

## DETAILED DESCRIPTION

### INTRODUCTION

The present invention is the discovery that sequence-non-specific double-stranded nucleic acid binding proteins can be joined to catalytic nucleic acid modifying proteins to enhance the processive nature of the catalytic protein. While the prior art taught 30 that nucleic acid binding proteins can increase the binding affinity of enzymes to nucleic acid, the group of binding proteins having the ability to enhance the processive nature of the enzymes is of particular value. Not to be bound by theory, binding domains of the invention typically dissociate from double-stranded nucleic acid at a very slow rate. Thus, they

increase the processivity and/or efficiency of a modifying enzyme to which they are joined by stabilizing the enzyme-nucleic acid complex. Accordingly, this invention includes the discovery that DNA-binding domains can stabilize the double-stranded conformation of a nucleic acid and increase the efficiency of a catalytic domain that requires a double-stranded substrate. Described herein are examples and simple assays to readily determine the improvement to the catalytic and/or processive nature of catalytic nucleic acid modifying enzymes.

#### CATALYTIC NUCLEIC-ACID-MODIFYING DOMAINS.

A catalytic nucleic-acid-modifying domain is the region of a modification enzyme that performs the enzymatic function. The catalytic nucleic-acid modifying domains of the invention can be processive, *e.g.*, polymerase, exonuclease, *etc.*, or non-processive, *e.g.*, ligases, restriction endonucleases, *etc.*

Processivity reflects the ability of a nucleic acid modifying enzyme to synthesize or perform multiple modifications, *e.g.*, nucleotide additions or methylations, in a single binding event. The processive proteins of the present invention exhibit enhanced processivity due to the presence of a sequence-non-specific double-stranded DNA binding domain that is joined to the processive modifying enzyme (or the enzymatic domain of the modifying enzyme), thereby providing a tethering domain to stabilize the nucleic acid/enzyme complex. Often the binding domain is from a thermostable organism and provides enhanced activity at higher temperatures, *e.g.*, temperatures above 45°C. Examples of processive modifying enzymes include DNA polymerases, RNA polymerases, reverse transcriptases, methylases, 3' or 5' exonucleases, gyrases, and topoisomerase.

#### 25 *Polymerases*

DNA polymerases are well-known to those skilled in the art. These include both DNA-dependent polymerases and RNA-dependent polymerases such as reverse transcriptase. At least five families of DNA-dependent DNA polymerases are known, although most fall into families A, B and C. There is little or no structural or sequence similarity among the various families. Most family A polymerases are single chain proteins that can contain multiple enzymatic functions including polymerase, 3' to 5' exonuclease activity and 5' to 3' exonuclease activity. Family B polymerases typically have a single catalytic domain with polymerase and 3' to 5' exonuclease activity, as well as accessory factors. Family C polymerases are typically multi-subunit proteins with polymerizing and 3'

to 5' exonuclease activity. In *E. coli*, three types of DNA polymerases have been found, DNA polymerases I (family A), II (family B), and III (family C). In eukaryotic cells, three different family B polymerases, DNA polymerases  $\alpha$ ,  $\delta$ , and  $\epsilon$ , are implicated in nuclear replication, and a family A polymerase, polymerase  $\gamma$ , is used for mitochondrial DNA 5 replication. Other types of DNA polymerases include phage polymerases.

Similarly, RNA polymerase typically include eukaryotic RNA polymerases I, II, and III, and bacterial RNA polymerases as well as phage and viral polymerases. RNA polymerases can be DNA-dependent and RNA-dependent.

In one embodiment, polymerase domains that have an error-correcting activity 10 are used as the catalytic domain of the improved polymerases described herein. These polymerases can be used to obtain long, *i.e.*, 5 kb, often 10 kb, or greater in length, PCR products. "Long PCR" using these improved polymerases can be performed using extension times that are reduced compared to prior art "long PCR" polymerase and/or polymerase mixtures. Extension times of less than 30 seconds per kb, often 15 seconds per kb, can be 15 used to amplify long products in PCR reactions using the improved polymerases.

Furthermore, these modified polymerases also exhibit increased sensitivity.

Prior-art non-error-correcting polymerases such as Taq polymerase are capable of amplifying DNA from very small input copy concentrations, such as, in the extreme, 10 copies per ml. However, because of the low fidelity of such polymerases, 20 products cloned from such amplifications are likely to contain introduced mutations.

Prior-art error-correcting polymerases such as Pfu copy DNA with higher fidelity than Taq, but are not capable of amplifying DNA from small input copy concentrations. The most likely explanation for such failure is the very low processivity of these enzymes. The hybrid error-correcting polymerases of the invention exhibit much 25 higher processivity while retaining error-correcting activity and thereby provide both sensitivity and fidelity in amplification reactions.

#### *Other modifying enzymes*

Typically, DNA gyrases and topoisomerases play a role in higher orders of 30 DNA structures such as supercoiling. DNA gyrases introduce negative supercoils. In prokaryotes, the A subunit is responsible for DNA cutting and reunion and the B subunit contains the ATP-hydrolysis activity. DNA gyrase introduces supercoiling processively and

catalytically, typically introducing up to 100 supercoils per minute per molecule of DNA gyrase. In the absence of ATP, gyrase will slowly relax negative supercoils.

Topoisomerases are enzymes found in both prokaryotes and eukaryotes that catalyze the interconversion of different topological isomers of DNA, thereby causing a 5 change in the link number. Topoisomerases can remove negative or positive supercoils from DNA or can introduce negative supercoils.

A variety of methylases and 3' or 5' exonucleases are also described in the art including bacterial, prokaryotic, eukaryotic and phage enzymes. Typically, exonucleases, such as lambda exonuclease, and some methylases are also processive.

10 The activity of a catalytic subunit can be measured using assays well known to those of skill in the art. For example, a processive enzymatic activity, such as a polymerase activity, can be measured by determining the amount of nucleic acid synthesized in a reaction, such as a polymerase chain reaction. In determining the relative efficiency of the enzyme, the amount of product obtained with a modifying enzyme of the invention, *e.g.* a 15 polymerase containing a sequence-non-specific double-stranded DNA binding domain, can then be compared to the amount of product obtained with the normal modifying enzyme, which will be described in more detail below and in the Examples.

Modifying enzymes such as ligases or restriction endonucleases bind to double-stranded nucleic acids to perform the modifying function. The catalytic activity is 20 typically measured by determining the amount of modified product produced under particular assay conditions. For example, ligase activity can be assayed by determining the amount of circularized plasmid, which had previously been digested with a restriction endonuclease to generate compatible ends, in a ligation reaction following incubation by quantifying the number of transformants obtained with an aliquot of the ligation reaction. Activity of a 25 restriction endonuclease can be determined by assaying the extent of digestion of the target DNA, for example, by analyzing the extent of digestion of the DNA on a gel.

A catalytic modifying domain suitable for use in the invention can be the modifying enzyme itself or the catalytic modifying domain, *e.g.*, Taq polymerase or a domain of Taq with polymerase activity. The catalytic domain may include additional amino acids 30 and/or may be a variant that contains amino acid substitutions, deletions or additions, but still retains enzymatic activity.

SEQUENCE-NON-SPECIFIC NUCLEIC-ACID-BINDING DOMAIN.

A double-stranded sequence-non-specific nucleic acid binding domain is a protein or defined region of a protein that binds to double-stranded nucleic acid in a sequence-independent manner, *i.e.*, binding does not exhibit a gross preference for a particular sequence. Typically, double-stranded nucleic acid binding proteins exhibit a 10-fold or higher affinity for double-stranded versus single-stranded nucleic acids. The double-stranded nucleic acid binding proteins in particular embodiments of the invention are preferably thermostable. Examples of such proteins include, but are not limited to, the Archaeal small basic DNA binding proteins Sac7d and Sso7d (*see, e.g.*, Choli *et al.*, 5 *Biochimica et Biophysica Acta* 950:193-203, 1988; Baumann *et al.*, *Structural Biol.* 1:808-10 819, 1994; and Gao *et al.*, *Nature Struc. Biol.* 5:782-786, 1998), Archaeal HMf-like proteins (see, *e.g.*, Starich *et al.*, *J. Molec. Biol.* 255:187-203, 1996; Sandman *et al.*, *Gene* 150:207-15 208, 1994), and PCNA homologs (*see, e.g.*, Cann *et al.*, *J. Bacteriology* 181:6591-6599, 1999; Shamoo and Steitz, *Cell*:99, 155-166, 1999; De Felice *et al.*, *J. Molec. Biol.* 291, 47-57, 1999; and Zhang *et al.*, *Biochemistry* 34:10703-10712, 1995).

*Sso7d and Sac7d*

Sso7d and Sac7d are small (about 7,000 kd MW), basic chromosomal proteins from the hyperthermophilic archaeabacteria *Sulfolobus solfataricus* and *S. acidocaldarius*, 20 respectively. These proteins are lysine-rich and have high thermal, acid and chemical stability. They bind DNA in a sequence-independent manner and when bound, increase the  $T_m$  of DNA by up to 40° C under some conditions (McAfee *et al.*, *Biochemistry* 34:10063-10077, 1995). These proteins and their homologs are typically believed to be involved in stabilizing genomic DNA at elevated temperatures.

25

*HMF-like proteins*

The HMf-like proteins are archaeal histones that share homology both in amino acid sequences and in structure with eukaryotic H4 histones, which are thought to interact directly with DNA. The HMf family of proteins form stable dimers in solution, and 30 several HMf homologs have been identified from thermostable species (*e.g.*, *Methanothermus fervidus* and *Pyrococcus* strain GB-3a). The HMf family of proteins, once joined to Taq DNA polymerase or any DNA modifying enzyme with a low intrinsic processivity, can enhance the ability of the enzyme to slide along the DNA substrate and thus increase its processivity. For example, the dimeric HMf-like protein can be covalently linked

to the N terminus of Taq DNA polymerase, *e.g.*, via chemical modification, and thus improve the processivity of the polymerase.

*PCNA homologs*

5 Many but not all family B DNA polymerases interact with accessory proteins to achieve highly processive DNA synthesis. A particularly important class of accessory proteins is referred to as the sliding clamp. Several characterized sliding clamps exist as trimers in solution, and can form a ring-like structure with a central passage capable of accommodating double-stranded DNA. The sliding clamp forms specific interactions with  
10 the amino acids located at the C terminus of particular DNA polymerases, and tethers those polymerases to the DNA template during replication. The sliding clamp in eukarya is referred to as the proliferating cell nuclear antigen (PCNA), while similar proteins in other domains are often referred to as PCNA homologs. These homologs have marked structural similarity but limited sequence similarity.

15 Recently, PCNA homologs have been identified from thermophilic Archaea (*e.g.*, *Sulfolobus sofaricus*, *Pyrococcus furiosus*, etc.). Some family B polymerases in Archaea have a C terminus containing a consensus PCNA-interacting amino acid sequence and are capable of using a PCNA homolog as a processivity factor (*see, e.g.*, Cann *et al.*, *J. Bacteriol.* 181:6591-6599, 1999 and De Felice *et al.*, *J. Mol. Biol.* 291:47-57, 1999). These  
20 PCNA homologs are useful sequence-non-specific double-stranded DNA binding domains for the invention. For example, a consensus PCNA-interacting sequence can be joined to a polymerase that does not naturally interact with a PCNA homolog, thereby allowing a PCNA homolog to serve as a processivity factor for the polymerase. By way of illustration, the PCNA-interacting sequence from *Pyrococcus furiosus* PolII (a heterodimeric DNA  
25 polymerase containing two family B-like polypeptides) can be covalently joined to *Pyrococcus furiosus* PolI (a monomeric family B polymerase that does not normally interact with a PCNA homolog). The resulting fusion protein can then be allowed to associate non-covalently with the *Pyrococcus furiosus* PCNA homolog to generate a novel heterologous protein with increased processivity relative to the unmodified *Pyrococcus furiosus* PolI.

30

*Other sequence-nonspecific double-stranded nucleic acid binding domains*

Additional nucleic acid binding domains suitable for use in the invention can be identified by homology with known sequence non-specific double-stranded DNA binding

proteins and/or by antibody crossreactivity, or may be found by means of a biochemical assay.

*Identification of nucleic acid binding domains based on homology.*

5       Typically, domains that have about 50% amino acid sequence identity, optionally about 60%, 75, 80, 85, 90, or 95-98% amino acid sequence identity to a known sequence non-specific double-stranded nucleic acid binding protein over a comparison window of about 25 amino acids, optionally about 50-100 amino acids, or the length of the entire protein, can be used in the invention. The sequence can be compared and aligned for  
10      maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. For purposes of this patent, percent amino acid identity is determined by the default parameters of BLAST.

15      For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences  
20      relative to the reference sequence, based on the program parameters.

25      The comparison window includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA*  
30      85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., *Current Protocols in Molecular Biology* (Ausubel et al., eds. 1995 supplement)).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a 5 simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with 10 the pair-wise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pair-wise alignment of two individual sequences. The final alignment is achieved by a series of 15 progressive, pair-wise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al.*, *Nuc. Acids Res.* 12:387-395 (1984)).

20 Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1977) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990), respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information 25 (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for 30 initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the

cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm 5 parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 10 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5877 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest 15 sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

20

#### *Cross-reactive binding to antibodies*

Sequence non-specific doubled-stranded nucleic acid binding domains for use in the invention can also be identified by cross-reactivity using antibodies, preferably polyclonal antibodies, that bind to known nucleic acid binding domains. Polyclonal 25 antibodies are generated using methods well known to those of ordinary skill in the art (see, e.g., Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies, A Laboratory Manual* (1988)). Those proteins that are immunologically cross-reactive binding proteins can then be detected by a variety of assay methods. For descriptions of various formats and conditions that can be used, see, e.g., *Methods in Cell Biology: Antibodies in Cell 30 Biology*, volume 37 (Asai, ed. 1993), Coligan, *supra*, and Harlow & Lane, *supra*.

Useful immunoassay formats include assays where a sample protein is immobilized to a solid support. For example, a cross-reactive binding protein can be identified using an immunoblot analysis such as a western blot. The western blot technique generally comprises separating sample proteins by gel electrophoresis on the basis of

molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that bind to the sequence non-specific double-stranded nucleic acid binding domain. The antibodies specifically bind to cross-reactive polypeptides on the solid support.

5 The antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-binding domain antibodies. Other immunoblot assays, such as analysis of recombinant protein libraries, are also useful for identifying proteins suitable for use in the invention.

Using this methodology under designated immunoassay conditions,

10 immunologically cross-reactive proteins that bind to a particular antibody at least two times the background or more, typically more than 10 times background, and do not substantially bind in a significant amount to other proteins present in the sample can be identified.

Immunoassays in the competitive binding format can also be used for crossreactivity determinations. For example, polyclonal antisera are generated to a known, 15 sequence non-specific double-stranded nucleic acid binding domain protein, e.g., a *Pyrococcus furiosus* (*Pfu*) PCNA. The target antigen can then be immobilized to a solid support. Non-target antigens having minor crossreactivity (if they exist) can be added to the assay to improve the selectivity of the sera. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the binding 20 domain protein, in this example *Pfu* PCNA, to compete with itself. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with the added protein are selected and pooled. Cross-reacting antibodies to non-target antigens can also be removed from the pooled antisera by immunoabsorption with the non-target antigens. Antibodies that specifically bind to 25 particular nucleic acid binding domains of the invention can also be made using this methodology.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele, polymorphic variant or a homolog of the known binding domain, for example, a 30 PCNA homolog from another *Pyrococcus* sp., to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the nucleic acid binding domain protein

that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies generated to the nucleic acid binding domain immunogen.

Assays for sequence non-specific double-stranded nucleic acid binding activity

5 The activity of the sequence non-specific double-stranded nucleic acid binding domains can be assessed using a variety of assays. Suitable binding domains exhibit a marked preference for double-stranded vs. single-stranded nucleic acids.

Specificity for binding to double-stranded nucleic acids can be tested using a variety of assays known to those of ordinary skill in the art. These include such assays as  
10 filter binding assays or gel-shift assays. For example, in a filter-binding assay the polypeptide to be assessed for binding activity to double-stranded DNA is pre-mixed with radio-labeled DNA, either double-stranded or single-stranded, in the appropriate buffer. The mixture is filtered through a membrane (e.g., nitrocellulose) which retains the protein and the protein-DNA complex. The amount of DNA that is retained on the filter is indicative of the  
15 quantity that bound to the protein. Binding can be quantified by a competition analysis in which binding of labeled DNA is competed by the addition of increasing amounts of unlabelled DNA. A polypeptide that binds double-stranded DNA at a 10-fold or greater affinity than single-stranded DNA is defined herein as a double-stranded DNA binding protein. Alternatively, binding activity can be assessed by a gel shift assay in which  
20 radiolabeled DNA is incubated with the test polypeptide. The protein-DNA complex will migrate slower through the gel than unbound DNA, resulting in a shifted band. The amount of binding is assessed by incubating samples with increasing amounts of double-stranded or single-stranded unlabeled DNA, and quantifying the amount of radioactivity in the shifted band.

25 A binding domain suitable for use in the invention binds to double-stranded nucleic acids in a sequence-independent fashion, i.e., a binding domain of the invention binds double-stranded nucleic acids with a significant affinity, but, there is no known nucleic acid that binds to the domain with more than 100-fold more affinity than another nucleic acid with the same nucleotide composition, but a different nucleic acid sequence. Non-specific binding  
30 can be assayed using methodology similar to that described for determining double-stranded vs. single-stranded nucleic acid binding. Filter binding assays or gel mobility shift assays can be performed as above using competitor DNAs of the same nucleotide composition, but different nucleic acid sequences to determine specificity of binding.

Sequence non-specific double-stranded nucleic acid binding domains for use in the invention can also be assessed, for example, by assaying the ability of the double-stranded binding domain to increase processivity or efficiency of a modifying enzyme or to increase the stability of a nucleic acid duplex by at least 1°C can be determined. These 5 techniques are discussed below in the section describing the analysis for enhanced efficiency of a nucleic acid modifying enzyme.

A binding domain of the invention can also be identified by direct assessment of the ability of such a domain to stabilize a double-stranded nucleic acid conformation. For example, a melting curve of a primer-template construct can be obtained in the presence or 10 absence of protein by monitoring the UV absorbance of the DNA at 260 nm. The  $T_M$  of the double-stranded substrate can be determined from the midpoint of the melting curve. The effect of the sequence-non-specific double-stranded nucleic-acid-binding protein on the  $T_M$  can then be determined by comparing the  $T_M$  obtained in the presence of the modified 15 enzyme with that in the presence of the unmodified enzyme. (The protein does not significantly contribute to the UV absorbance because it has a much lower extinction coefficient at 260 nm than DNA). A domain that increases the  $T_M$  by 1°, often by 5°, 10° or more, can then be selected for use in the invention.

Novel sequence non-specific double-stranded nucleic acid binding proteins of the invention can also be isolated by taking advantage of their DNA binding activity, for 20 instance by purification on DNA-cellulose columns. The isolated proteins can then be further purified by conventional means, sequenced, and the genes cloned by conventional means via PCR. Proteins overexpressed from these clones can then be tested by any of the means described above.

25 **JOINING THE CATALYTIC DOMAIN WITH THE NUCLEIC-ACID-BINDING DOMAIN.**

The catalytic domain and the double-stranded nucleic-acid-binding domain can be joined by methods well known to those of skill in the art. These methods include chemical and recombinant means.

30 Chemical means of joining the heterologous domains are described, e.g., in *Bioconjugate Techniques*, Hermanson, Ed., Academic Press (1996). These include, for example, derivitization for the purpose of linking the moieties to each other, either directly or through a linking compound, by methods that are well known in the art of protein chemistry. For example, in one chemical conjugation embodiment, the means of linking the catalytic

domain and the nucleic acid binding domain comprises a heterobifunctional coupling reagent which ultimately contributes to formation of an intermolecular disulfide bond between the two moieties. Other types of coupling reagents that are useful in this capacity for the present invention are described, for example, in U.S. Patent 4,545,985. Alternatively, an

5 intermolecular disulfide may conveniently be formed between cysteines in each moiety, which occur naturally or are inserted by genetic engineering. The means of linking moieties may also use thioether linkages between heterobifunctional crosslinking reagents or specific low pH cleavable crosslinkers or specific protease cleavable linkers or other cleavable or noncleavable chemical linkages.

10 The means of linking the heterologous domains of the protein may also comprise a peptidyl bond formed between moieties that are separately synthesized by standard peptide synthesis chemistry or recombinant means. The protein itself can also be produced using chemical methods to synthesize an amino acid sequence in whole or in part. For example, peptides can be synthesized by solid phase techniques, such as, e.g., the

15 Merrifield solid phase synthesis method, in which amino acids are sequentially added to a growing chain of amino acids (see, Merrifield (1963) *J. Am. Chem. Soc.*, 85:2149-2146). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as PE Corp. (Foster City, CA), and may generally be operated according to the manufacturer's instructions. The synthesized peptides can then be cleaved from the resin, 20 and purified, e.g., by preparative high performance liquid chromatography (see Creighton, *Proteins Structures and Molecular Principles*, 50-60 (1983)). The composition of the synthetic polypeptides or of subfragments of the polypeptide, may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, *Proteins, Structures and Molecular Principles*, pp. 34-49 (1983)).

25 In addition, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the sequence. Non-classical amino acids include, but are not limited to, the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxy-30 proline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids,  $\text{Ca}$ -methyl amino acids,  $\text{Na}$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

In another embodiment, the domains of a protein of the invention, *e.g.*, Sso7d and Taq polymerase, are joined via a linking group. The linking group can be a chemical crosslinking agent, including, for example, succinimidyl-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC). The linking group can also be an additional amino acid sequence(s), 5 including, for example, a polyalanine, polyglycine or similarly, linking group.

In a specific embodiment, the coding sequences of each polypeptide in the fusion protein are directly joined at their amino- or carboxy-terminus via a peptide bond in any order. Alternatively, an amino acid linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each 10 polypeptide folds into its secondary and tertiary structures. Such an amino acid linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and 15 (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Typical peptide linker sequences contain Gly, Val and Thr residues. Other near neutral amino acids, such as Ser and Ala can also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea *et al.* (1985) *Gene* 40:39-46; Murphy *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 20 83:8258-8262; U.S. Patent Nos. 4,935,233 and 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length, *e.g.*, 3, 4, 6, or 10 amino acids in length, but can be 100 or 200 amino acids in length. Linker sequences may not be required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

25 Other chemical linkers include carbohydrate linkers, lipid linkers, fatty acid linkers, polyether linkers, *e.g.*, PEG, *etc.* For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Alabama. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.

Other methods of joining the domains include ionic binding by expressing 30 negative and positive tails and indirect binding through antibodies and streptavidin-biotin interactions. (*See, e.g.*, *Bioconjugate Techniques, supra*). The domains may also be joined together through an intermediate interacting sequence. For example, a consensus PCNA-interacting sequence can be joined to a polymerase that does not naturally interact with a PCNA homolog. The resulting fusion protein can then be allowed to associate non-

covalently with the PCNA homolog to generate a novel heterologous protein with increased processivity.

*Production of fusion proteins using recombinant techniques*

5 In one embodiment, a protein of the invention is produced by recombinant expression of a nucleic acid encoding the protein, which is well known to those of skill in the art. Such a fusion product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the product by methods known in the art.

10 Nucleic acids encoding the domains to be incorporated into the fusion proteins of the invention can be obtained using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* 15 (Ausubel *et al.*, eds., 1994)).

Often, the nucleic acid sequences encoding catalytic or nucleic acid binding domains or related nucleic acid sequence homologs are cloned from cDNA and genomic DNA libraries by hybridization with probes, or isolated using amplification techniques with oligonucleotide primers. Amplification techniques can be used to amplify and isolate 20 sequences from DNA or RNA (see, e.g., Dieffenbach & Dveksler, *PCR Primers: A Laboratory Manual* (1995)). Alternatively, overlapping oligonucleotides can be produced synthetically and joined to produce one or more of the domains. Nucleic acids encoding catalytic or double-stranded nucleic acid binding domains can also be isolated from expression libraries using antibodies as probes.

25 In an example of obtaining a nucleic acid encoding a catalytic or nucleic acid binding domain using PCR, the nucleic acid sequence or subsequence is PCR amplified, using a sense primer containing one restriction site and an antisense primer containing another restriction site. This will produce a nucleic acid encoding the desired domain sequence or subsequence and having terminal restriction sites. This nucleic acid can then be 30 easily ligated into a vector containing a nucleic acid encoding the second domain and having the appropriate corresponding restriction sites. The domains can be directly joined or may be separated by a linker, or other, protein sequence. Suitable PCR primers can be determined by one of skill in the art using the sequence information provided in GenBank or other sources.

Appropriate restriction sites can also be added to the nucleic acid encoding the protein or protein subsequence by site-directed mutagenesis. The plasmid containing the domain-encoding nucleotide sequence or subsequence is cleaved with the appropriate restriction endonuclease and then ligated into an appropriate vector for amplification and/or expression 5 according to standard methods.

Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.*, eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson 10 (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3: 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem.*, 35: 1826; Landegren *et al.*, (1988) *Science* 241: 1077-1080; Van Brunt (1990) *Biotechnology* 8: 291-294; Wu and Wallace (1989) *Gene* 4: 560; and Barringer *et al.* (1990) *Gene* 89: 117.

15 Other physical properties of a polypeptide expressed from a particular nucleic acid can be compared to properties of known sequence nonspecific double-stranded nucleic acid binding proteins or nucleic acid modifying enzyme catalytic domains to provide another method of identifying suitable nucleic acids.

In some embodiments, it may be desirable to modify the polypeptides 20 encoding the catalytic and/or nucleic acid binding regions of the recombinant fusion protein. One of skill will recognize many ways of generating alterations in a given nucleic acid construct. Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (e.g., in conjunction with 25 ligation and/or cloning to generate large nucleic acids) and other well-known techniques. See, e.g., Giliman and Smith (1979) *Gene* 8:81-97, Roberts *et al.* (1987) *Nature* 328: 731-734.

For example, the catalytic and/or nucleic acid binding domains can be 30 modified to facilitate the linkage of the two domains to obtain the polynucleotides that encode the fusion polypeptides of the invention. Catalytic domains and binding domains that are modified by such methods are also part of the invention. For example, a codon for a cysteine residue can be placed at either end of a domain so that the domain can be linked by,

for example, a sulfide linkage. The modification can be performed using either recombinant or chemical methods (see, e.g., Pierce Chemical Co. catalog, Rockford IL).

The catalytic and binding domains of the recombinant fusion protein are often joined by linker domains, usually polypeptide sequences such as those described above, 5 which can be about 200 amino acids or more in length, with 1 to 100 amino acids being typical. In some embodiments, proline residues are incorporated into the linker to prevent the formation of significant secondary structural elements by the linker. Linkers can often be flexible amino acid subsequences that are synthesized as part of a recombinant fusion protein. Such flexible linkers are known to persons of skill in the art.

10 In some embodiments, the recombinant nucleic acids the recombinant nucleic acids encoding the proteins of the invention are modified to provide preferred codons which enhance translation of the nucleic acid in a selected organism (e.g., yeast preferred codons are substituted into a coding nucleic acid for expression in yeast).

15 *Expression cassettes and host cells for expressing the fusion polypeptides*

There are many expression systems for producing the fusion polypeptide that are well known to those of ordinary skill in the art. (See, e.g., Gene Expression Systems, Fernandex and Hoeffler, Eds. Academic Press, 1999.) Typically, the polynucleotide that encodes the fusion polypeptide is placed under the control of a promoter that is functional in 20 the desired host cell. An extremely wide variety of promoters are available, and can be used in the expression vectors of the invention, depending on the particular application. Ordinarily, the promoter selected depends upon the cell in which the promoter is to be active. Other expression control sequences such as ribosome binding sites, transcription termination sites and the like are also optionally included. Constructs that include one or more of these 25 control sequences are termed "expression cassettes." Accordingly, the nucleic acids that encode the joined polypeptides are incorporated for high level expression in a desired host cell.

30 Expression control sequences that are suitable for use in a particular host cell are often obtained by cloning a gene that is expressed in that cell. Commonly used prokaryotic control sequences, which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (*lac*) promoter systems (Change *et al.*, *Nature* (1977) 198: 1056), the tryptophan (*trp*)

promoter system (Goeddel *et al.*, *Nucleic Acids Res.* (1980) 8: 4057), the *tac* promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* (1983) 80:21-25); and the lambda-derived  $P_L$  promoter and N-gene ribosome binding site (Shimatake *et al.*, *Nature* (1981) 292: 128). The particular promoter system is not critical to the invention, any available promoter that 5 functions in prokaryotes can be used. Standard bacterial expression vectors include plasmids such as pBR322-based plasmids, *e.g.*, pBLUESCRIPT<sup>TM</sup>, pSKF, pET23D,  $\lambda$ -phage derived vectors, and fusion expression systems such as GST and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, *e.g.*, c-myc, HA-tag, 6-His tag, maltose binding protein, VSV-G tag, anti-DYKDDDDK tag, or any such tag, a 10 large number of which are well known to those of skill in the art.

For expression of fusion polypeptides in prokaryotic cells other than *E. coli*, a promoter that functions in the particular prokaryotic species is required. Such promoters can be obtained from genes that have been cloned from the species, or heterologous promoters can be used. For example, the hybrid *trp-lac* promoter functions in *Bacillus* in addition to *E. coli*. These and other suitable bacterial promoters are well known in the art and are 15 described, *e.g.*, in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for expressing the proteins of the invention are available in, *e.g.*, *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available.

20 Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. In yeast, vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp series plasmids) and pGPD-2. Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, *e.g.*, SV40 vectors, papilloma virus vectors, 25 and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+, pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown 30 effective for expression in eukaryotic cells.

Either constitutive or regulated promoters can be used in the present invention. Regulated promoters can be advantageous because the host cells can be grown to high

densities before expression of the fusion polypeptides is induced. High level expression of heterologous proteins slows cell growth in some situations. An inducible promoter is a promoter that directs expression of a gene where the level of expression is alterable by environmental or developmental factors such as, for example, temperature, pH, anaerobic or aerobic conditions, light, transcription factors and chemicals.

5 For *E. coli* and other bacterial host cells, inducible promoters are known to those of skill in the art. These include, for example, the *lac* promoter, the bacteriophage lambda P<sub>L</sub> promoter, the hybrid *trp-lac* promoter (Amann *et al.* (1983) *Gene* 25: 167; de Boer *et al.* (1983) *Proc. Nat'l. Acad. Sci. USA* 80: 21), and the bacteriophage T7 promoter 10 (Studier *et al.* (1986) *J. Mol. Biol.*; Tabor *et al.* (1985) *Proc. Nat'l. Acad. Sci. USA* 82: 1074-8). These promoters and their use are discussed in Sambrook *et al.*, *supra*.

Inducible promoters for other organisms are also well known to those of skill in the art. These include, for example, the metallothionein promoter, the heat shock promoter, as well as many others.

15 Translational coupling may be used to enhance expression. The strategy uses a short upstream open reading frame derived from a highly expressed gene native to the translational system, which is placed downstream of the promoter, and a ribosome binding site followed after a few amino acid codons by a termination codon. Just prior to the termination codon is a second ribosome binding site, and following the termination codon is a 20 start codon for the initiation of translation. The system dissolves secondary structure in the RNA, allowing for the efficient initiation of translation. See Squires, *et. al.* (1988), *J. Biol. Chem.* 263: 16297-16302.

The construction of polynucleotide constructs generally requires the use of 25 vectors able to replicate in bacteria. Such vectors are commonly used in the art. A plethora of kits are commercially available for the purification of plasmids from bacteria (for example, EasyPrepJ, FlexiPrepJ, from Pharmacia Biotech; StrataCleanJ, from Stratagene; and, QIAexpress Expression System, Qiagen). The isolated and purified plasmids can then be further manipulated to produce other plasmids, and used to transform cells.

The fusion polypeptides can be expressed intracellularly, or can be secreted 30 from the cell. Intracellular expression often results in high yields. If necessary, the amount of soluble, active fusion polypeptide may be increased by performing refolding procedures (see, e.g., Sambrook *et al.*, *supra*; Marston *et al.*, *Bio/Technology* (1984) 2: 800; Schoner *et*

al., *Bio/Technology* (1985) 3: 151). Fusion polypeptides of the invention can be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The host cells can be mammalian cells, insect cells, or microorganisms, such as, for example, 5 yeast cells, bacterial cells, or fungal cells.

Once expressed, the recombinant fusion polypeptides can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in 10 Enzymology Vol. 182: Guide to Protein Purification*, Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred. Once purified, partially or to homogeneity as desired, the polypeptides may then be used (e.g., as immunogens for antibody production).

15 To facilitate purification of the fusion polypeptides of the invention, the nucleic acids that encode the fusion polypeptides can also include a coding sequence for an epitope or "tag" for which an affinity binding reagent is available. Examples of suitable epitopes include the myc and V-5 reporter genes; expression vectors useful for recombinant production of fusion polypeptides having these epitopes are commercially available (e.g., 20 Invitrogen (Carlsbad CA) vectors pcDNA3.1/Myc-His and pcDNA3.1/V5-His are suitable for expression in mammalian cells). Additional expression vectors suitable for attaching a tag to the fusion proteins of the invention, and corresponding detection systems are known to those of skill in the art, and several are commercially available (e.g., FLAG" (Kodak, Rochester NY). Another example of a suitable tag is a polyhistidine sequence, which is 25 capable of binding to metal chelate affinity ligands. Typically, six adjacent histidines are used, although one can use more or less than six. Suitable metal chelate affinity ligands that can serve as the binding moiety for a polyhistidine tag include nitrilo-tri-acetic acid (NTA) (Hochuli, E. (1990) "Purification of recombinant proteins with metal chelating adsorbents" In Genetic Engineering: Principles and Methods, J.K. Setlow, Ed., Plenum Press, NY; 30 commercially available from Qiagen (Santa Clarita, CA)).

One of skill would recognize that modifications could be made to the catalytic and sequence nonspecific double-stranded nucleic acid binding domains without diminishing

their biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of a domain into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, the addition of codons at either terminus of the polynucleotide that encodes the binding domain to provide, for example, a 5 methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.

ASSAYS TO DETERMINE IMPROVED ACTIVITY FOR THE CATALYTIC DOMAINS.

10 Activity of the catalytic domain can be measured using a variety of assays that can be used to compare processivity or modification activity of a modifying protein domain joined to a binding domain compared to the protein by itself. Improvement in activity includes both increased processivity and increased efficiency.

15 *Improved activity of processive modifying enzymes*

Polymerase processivity can be measured in variety of methods known to those of ordinary skill in the art. Polymerase processivity is generally defined as the number of nucleotides incorporated during a single binding event of a modifying enzyme to a primed template.

20 For example, a 5' FAM-labeled primer is annealed to circular or linearized ssM13mp18 DNA to form a primed template. In measuring processivity, the primed template usually is present in significant molar excess to the enzyme or catalytic domain to be assayed so that the chance of any primed template being extended more than once by the polymerase is minimized. The primed template is therefore mixed with the polymerase 25 catalytic domain to be assayed at a ratio such as approximately 4000:1 (primed DNA:DNA polymerase) in the presence of buffer and dNTPs. MgCl<sub>2</sub> is added to initiate DNA synthesis. Samples are quenched at various times after initiation, and analyzed on a sequencing gel. At a polymerase concentration where the median product length does not change with time or 30 polymerase concentration, the length corresponds to the processivity of the enzyme. The processivity of a protein of the invention, i.e., a protein that contains a sequence non-specific double-stranded nucleic acid binding domain fused to the catalytic domain of a processive nucleic acid modifying enzyme such as a polymerase, is then compared to the processivity of the enzyme without the binding domain.

Enhanced efficiency can also be demonstrated by measuring the increased ability of an enzyme to produce product. Such an analysis measures the stability of the double-stranded nucleic acid duplex indirectly by determining the amount of product obtained in a reaction. For example, a PCR assay can be used to measure the amount of PCR product obtained with a short, e.g., 12 nucleotide in length, primer annealed at an elevated temperature, e.g., 50°C. In this analysis, enhanced efficiency is shown by the ability of a polymerase such as a Taq polymerase to produce more product in a PCR reaction using the 12 nucleotide primer annealed at 50°C when it is joined to a sequence-non-specific double-stranded nucleic-acid-binding domain of the invention, e.g., Sso7d, than Taq polymerase does alone. In contrast, a binding tract that is a series of charged residues, e.g. lysines, when joined to a polymerase does not enhance processivity.

Similar assay conditions can be employed to test for improved processivity when the catalytic domain is a reverse transcriptase, methylase, gyrase, topoisomerase, or an exonuclease. In these analyses, processivity is measured as the ability of the enzyme to remain attached to the template or substrate and perform multiple modification reactions. The molar ratio of nucleic acid to enzyme is typically sufficiently high so that on the average only one enzyme molecule is bound per substrate nucleic acid. For example, the activity of a processive exonuclease, lambda exonuclease, can be assayed using published methods (see, e.g., Mitsis and Kwagh, *Nucleic Acid Research*, 27:3057-3063, 1999). In brief, a long DNA substrates (0.5-20 kb) can be amplified from a DNA template using a 5'-biotinylated primer as the forward primer and a 5' phosphorylated primer as the reverse primer, or *vice versa*. Radio-labeled dATP is used to internally label the PCR fragment, which serves as the substrate for the lambda exonuclease. The purified internally-labeled substrate is mixed with the enzyme at a sufficient high molar ratio of DNA to enzyme to ensure that on average only one exonuclease molecule bound per substrate DNA. Aliquots of the sample are removed over time and can be assayed either by gel electrophoresis or by monitoring the formation of acid soluble radio-labels.

#### *Enhanced activity of non-processive modifying enzymes*

Catalytic domains of non-processive DNA modifying enzymes, or the enzymes themselves, can also be used in the invention. Examples of such modifying enzymes include ligases and restriction endonucleases. Often, the catalytic domains are obtained from thermostable *Thermus* or *Pyrococcus* species. To determine improved activity, the enzymatic function can be analyzed under a variety of conditions, often

increased reaction temperatures, *e.g.*, temperatures 45°C or above, and compared to the unmodified enzyme activity.

For example, Taq DNA ligase catalyzes the formation of a phosphodiester bond between juxtaposed 5' phosphate and 3' hydroxyl termini of two adjacent

5 oligonucleotides that are hybridized to a complementary target DNA. The enzyme is active at 45°C-65°C. The yield of the ligated product is dependent on how efficiently the complementary strands of DNA are annealed to form the substrate for the enzyme. A binding domain of the invention, such as a Sso7d-like protein, when joined to the ligase can stabilize the DNA duplex by increasing its melting temperature, so that an elevated reaction  
10 temperature can be used to maximize the activity of the enzyme without compromising the basepairing interactions.

The effect of Sso7d fusion on the activity of a ligase can be analyzed by comparing the ligation efficiency of the modified versus that of the unmodified enzyme. The ligation efficiency of two linear DNA fragments can be monitored by agarose gel  
15 electrophoresis, whereas the ligation efficiency of converting a linearized plasmid to a circular plasmid can be monitored by DNA transformation.

In another example, the catalytic domain of a nucleic acid modifying enzyme with improved activity can be from a restriction enzyme isolated from a thermophilic species that requires an elevated reaction temperature to achieve optimal activity. For example when  
20 the restriction enzyme recognition sites are located very close to the end of a DNA fragment or in duplexed oligonucleotides, higher temperatures may destabilize the duplex structure. At a higher reaction temperature, *e.g.*, 45°C or above, a restriction enzyme with improved activity because of the presence of a binding domain of the invention, *e.g.*, an Sso7d-like protein joined to the restriction endonuclease, can produce a greater amount of product, *i.e.*,  
25 digested DNA, than the restriction enzyme by itself. The product yield from a particular reaction can be assessed by visualization on a gel or by assessment of transformation efficiency.

Other methods of assessing enhanced efficiency of the improved nucleic acid modifying enzymes of the invention can be determined by those of ordinary skill in the art  
30 using standard assays of the enzymatic activity of a given modification enzyme. Thus, processive modifying enzymes such as reverse transcriptases, methylases, gyrases, and topoisomerases, and other non-processive modifying enzymes can be similarly analyzed by comparing activities of the protein, or a catalytic domain, joined to a sequence non-specific double-stranded nucleic acid binding domain and the protein by itself.

All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

5 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

10

### EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially similar results.

15 **Example 1. Construction of fusion proteins.**

*Construction of Sso7d-ΔTaq fusion.*

20 The following example illustrates the construction of a polymerase protein possessing enhanced processivity, in which the sequence-non-specific double-stranded nucleic acid binding protein Sso7d is fused to the *Thermus aquaticus* PolI DNA polymerase (a family A polymerase known as Taq DNA polymerase) that is deleted at the N terminus by 289 amino acids (ΔTaq).

25 Based on the published amino acid sequence of Sso7d, seven oligonucleotides were used in constructing a synthetic gene encoding Sso7d. The oligonucleotides were annealed and ligated using T4 DNA ligase. The final ligated product was used as the template in a PCR reaction using two terminal oligonucleotides as primers to amplify the full-length gene. By design, the resulting PCR fragment contains a unique EcoRI site at the 5' terminus, and a unique BstXI site at the 3' terminus. In addition to encoding the Sso7d protein, the above PCR fragment also encodes a peptide linker with the amino acid sequence of Gly-Gly-Val-Thr positioned at the C terminus of the Sso7d protein. The synthetic gene of 30 Sso7d has the DNA sequence shown in SEQ ID NO:1, and it encodes a polypeptide with the amino acid sequence shown in SEQ ID NO:2.

The synthetic gene encoding Sso7d was then used to generate a fusion protein in which Sso7d replaces the first 289 amino acid of Taq. The fragment encoding Sso7d was

subcloned into a plasmid encoding Taq polymerase to generate the fusion protein, as follows. Briefly, the DNA fragment containing the synthetic Sso7d gene was digested with restriction endonucleases EcoRI and BstXI, and ligated into the corresponding sites of a plasmid encoding Taq. As the result, the region that encodes the first 289 amino acid of Taq is 5 replaced by the synthetic gene of Sso7d. This plasmid (pYW1) allows the expression of a single polypeptide containing Sso7d fused to the N terminus of  $\Delta$ Taq via a synthetic linker composed of Gly-Gly-Val-Thr. The DNA sequence encoding the fusion protein (Sso7d- $\Delta$ Taq) and the amino acid sequence of the protein are shown in SEQ ID NOs:3 and 4, respectively.

10 *Construction of Sso7d-Taq fusion.*

An Sso7d/full-length Taq fusion protein was also constructed. Briefly, a 1 kb PCR fragment encoding the first 336 amino acids of Taq polymerase was generated using two primers. The 5' primer introduces a SpeI site into the 5' terminus of the PCR fragment, and the 3' primer hybridizes to nucleotides 1008-1026 of the Taq gene. The fragment was 15 digested with SpeI and BstXI, releasing a 0.9 kb fragment encoding the first 289 amino acids of Taq polymerase. The 0.9 kb fragment was ligated into plasmid pYW1 at the SpeI (located in the region encoding the linker) and BstXI sites. The resulting plasmid (pYW2) allows the expression of a single polypeptide containing the Sso7d protein fused to the N terminus of the full length Taq DNA polymerase via a linker composed of Gly-Gly-Val-Thr, the same as in 20 Sso7d- $\Delta$ Taq. The DNA sequence encoding the Sso7d-Taq fusion protein and the amino acid sequence of the protein are shown in SEQ ID. NO.5 and NO.6, respectively.

*Construction of Pfu-Sso7d fusion.*

A third fusion protein was created, joining Sso7d to the C terminus of *Pyrococcus furiosus* DNA polII (a family B DNA polymerase known as Pfu). A pET-based 25 plasmid carrying the Pfu DNA polymerase gene was modified so that a unique KpnI site and a unique SpeI site are introduced at the 3' end of the Pfu gene before the stop codon. The resulting plasmid (pPFKS) expresses a Pfu polymerase with three additional amino acids (Gly-Thr-His) at its C terminus.

Two primers were used to PCR amplify the synthetic Sso7d gene described 30 above to introduce a KpnI site and a NheI site flanking the Sso7d gene. The 5' primer also introduced six additional amino acids (Gly-Thr-Gly-Gly-Gly-Gly), which serve as a linker, at the N terminus of the Sso7d protein. Upon digestion with KpnI and NheI, the PCR fragment was ligated into pPFKS at the corresponding sites. The resulting plasmid (pPFS) allows the

expression of a single polypeptide containing Sso7d protein fused to the C terminus of the Pfu polymerase via a peptide linker (Gly-Thr-Gly-Gly-Gly). The DNA sequence encoding the fusion protein (Pfu-Sso7d) and the amino acid sequence of the fusion protein are shown in SEQ ID NOs: 7 and 8, respectively.

5 ***Construction of Sac7d-ΔTaq fusion.***

A fourth fusion protein was constructed, which joined a sequence-non-specific DNA binding protein from a different species to ΔTaq. Two primers were used to PCR amplify the Sac7d gene from genomic DNA of *Sulfolobus acidocaldarius*. The primers introduced a unique EcoRI site and a unique SpeI site to the PCR fragment at the 5' and 3' 10 termini, respectively. Upon restriction digestion with EcoRI and SpeI, the PCR fragment was ligated into pYW1 (described above) at the corresponding sites. The resulting plasmid expresses a single polypeptide containing the Sac7d protein fused to the N terminus of ΔTaq via the same linker as used in Sso7d-ΔTaq. The DNA sequence of the fusion protein (Sac7d-ΔTaq) and the amino acid sequence of the protein are shown in SEQ ID. NOs: 9 and 10, 15 respectively.

***Construction of PL-ΔTaq fusion.***

A fifth fusion protein joins a peptide composed of 14 lysines and 2 arginines to the N terminus of ΔTaq. To generate the polylysine (PL)-ΔTaq fusion protein, two 67 nt oligonucleotides were annealed to form a duplexed DNA fragment with a 5' protruding end 20 compatible with an EcoRI site, and a 3' protruding end compatible with an SpeI site. The DNA fragment encodes a lysine-rich peptide of the following composition: NSKKKKKKRKRRKKKGGSVT. The numbers of lysines and arginines in this peptide are identical to the that in Sso7d. This DNA fragment was ligated into pYW1, predigested with EcoRI and SpeI, to replace the region encoding Sso7d. The resulting plasmid (pLST) 25 expresses a single polypeptide containing the lysine-rich peptide fused to the N terminus of ΔTaq. The DNA sequence encoding the fusion protein (PL-ΔTaq) and the amino acid sequence of the protein are shown in SEQ ID NOs: 11 and NO. 12, respectively.

**Example 2. Assessing the processivity of the fusion polymerases.**

30 This example illustrates enhancement of processivity of the fusion proteins of the invention generated in Example 1.

***Polymerase unit definition assay***

The following assay was used to define a polymerase unit. An oligonucleotide was pre-annealed to ssM13mp18 DNA in the presence of  $Mg^{++}$ -free reaction buffer and dNTPs. The DNA polymerase of interest was added to the primed DNA mixture.  $MgCl_2$  was added to initiate DNA synthesis at 72°C. Samples were taken at various time points and added to TE buffer containing PicoGreen (Molecular Probes, Eugene Oregon). The amount of DNA synthesized was quantified using a fluorescence plate reader. The unit activity of the DNA polymerase of interest was determined by comparing its initial rate with that of a control DNA polymerase (e.g., a commercial polymerase of known unit concentration).

**10 *Processivity assay***

Processivity was measured by determining the number of nucleotides incorporated during a single binding event of the polymerase to a primed template.

Briefly, 40 nM of a 5' FAM-labeled primer (34 nt long) was annealed to 80 nM of circular or linearized ssM13mp18 DNA to form the primed template. The primed template was mixed with the DNA polymerase of interest at a molar ratio of approximately 4000:1 (primed DNA:DNA polymerase) in the presence of standard PCR buffer (free of  $Mg^{++}$ ) and 200  $\mu$ M of each dNTPs.  $MgCl_2$  was added to a final concentration of 2 mM to initiate DNA synthesis. At various times after initiation, samples were quenched with sequencing loading dye containing 99% formamide, and analyzed on a sequencing gel. The median product length, which is defined as the product length above or below which there are equal amounts of products, was determined based on integration of all detectable product peaks. At a polymerase concentration for which the median product length change with time or polymerase concentration, the length corresponds to the processivity of the enzyme. The ranges presented in Table 1 represent the range of values obtained in several repeats of the assay.

Table I. Comparison of processivity

DNA polymerase	Median product length (nt)
$\Delta$ Taq	2-6
Sso7d- $\Delta$ Taq	39-58
PL- $\Delta$ Taq	2-6
Taq	15-20
Sso7d-Taq	130-160
Pfu	2-3
Pfu-Sso7d	35-39

5 In comparing the processivity of modified enzyme to the unmodified enzyme,  $\Delta$ Taq had a processivity of 2-6 nucleotides, whereas Sso7d- $\Delta$ Taq fusion exhibited a processivity of 39-58 nucleotides (Table I). Full length Taq had a processivity of 15-20 nucleotides, which was significantly lower than that of Sso7d-Taq fusion with a processivity of 130-160 nucleotides. These results demonstrate that Sso7d joined to Taq polymerase enhanced the processivity of the polymerase.

10 Pfu belongs to family B of polymerases. Unlike Taq polymerase, Pfu possesses a 3' to 5' exonuclease activity, allowing it to maintain high fidelity during DNA synthesis. A modified Pfu polymerase, in which Sso7d is fused to the C terminus of the full length Pfu polymerase, and an unmodified Pfu polymerase were analyzed in the processivity assay described above. As shown in Table I, the Pfu polymerase exhibited a processivity of 2-3 nt, whereas the Pfu-Sso7d fusion protein had a processivity of 35-39 nt. Thus, the fusion of Sso7d to the C terminus of Pfu resulted in a >10-fold enhancement of the processivity over the unmodified enzyme.

15 The ability of a lysine-rich peptide to enhance the processivity of Taq polymerase was also assessed. The processivity of PL- $\Delta$ Taq was measured using the method described above, and compared to that of the unmodified protein,  $\Delta$ Taq. As shown in Table I, the presence of the polylysine tract did not enhance the processivity of  $\Delta$ Taq. Thus, although the addition of a lysine-rich peptide to a nucleic acid binding protein may increase 20 the association rate of an enzyme to its substrate as disclosed in the prior art, processivity is not increased.

#### Example 3. Effect of fusion proteins on oligonucleotide annealing temperature

25 This experiment demonstrates the increased efficiency of the Sso7d- $\Delta$ Taq fusion protein, compared to Taq, to produce product at higher annealing temperatures by stabilizing dsDNA.

30 Two primers, primer 1008 (19mer;  $T_m$  = 56.4°C) and 2180R (20mer;  $T_m$  = 56.9°C), were used to amplify a 1 kb fragment (1008-2180) of the Taq pol gene. A gradient thermal cycler (MJ Research, Waltham MA) was used to vary the annealing temperature from 50°C to 72°C in a PCR cycling program. The amounts of PCR products generated using identical number of units of Sso7d- $\Delta$ Taq and Taq were quantified and compared. The results are shown in Table II. The Sso7d- $\Delta$ Taq fusion protein exhibited significantly higher

efficiency than full length Taq at higher annealing temperatures. Thus, the presence of Sso7d in *cis* increases the melting temperature of the primer on the template.

The annealing temperature assay above was used to investigate whether PL- $\Delta$ Taq has any effect on the annealing temperature of primer during PCR amplification. As shown in Table II, little or no amplified product was observed when the annealing temperature was at or above 63°C.

Table II. Comparison of activities at different annealing temperatures.

Polymerase	Activity at 63°C	Activity at 66°C	Activity at 69°C
Taq	85%	30%	<10%
Sso7d- $\Delta$ Taq	>95%	70%	40%
PL- $\Delta$ Taq	<5%	nd	nd

nd: not detectable.

10

**Example 4. Effect of fusion proteins on required primer length**

An enhancement of  $T_m$  of the primers (as shown above) predicts that shorter primers could be used by Sso7d- $\Delta$ Taq, but not by Taq, to achieve efficient PCR amplification. This analysis shows that Sso7d- $\Delta$ Taq is more efficient in an assay using shorter primers compared to Taq.

Primers of different lengths were used to compare the efficiencies of PCR amplification by Sso7d- $\Delta$ Taq and by Taq. The results are shown in Table III and in Figure 1A-1C. When two long primers, 57F (22mer,  $T_m$  = 58°C) and 732R (24mer,  $T_m$  = 57°C) were used, no significant difference was observed between Sso7d- $\Delta$ Taq and Taq at either low or high annealing temperatures. When medium length primers, 57F15 (15mer,  $T_m$  = 35°C) and 732R16 (16mer,  $T_m$  = 35°C), were used, Sso7d- $\Delta$ Taq was more efficient than Taq, especially when the annealing temperature was high. The most striking difference between the two enzymes was observed with short primers, 57F12 (12mer) and 732R16 (16mer), where Sso7d- $\Delta$ Taq generated 10 times more products than Taq at both low and high annealing temperatures.

PCR using primers 57F12 (12 nt) and 732R16 (16 nt) were used to compare the efficiency of Sac7d- $\Delta$ Taq to the unmodified full length Taq in PCR reaction. Results are shown in Figure 2. Similar to Sso7d- $\Delta$ Taq, Sac7d- $\Delta$ Taq is significantly more efficient than Taq in amplifying using short primers.

A primer length assay was used to determine the ability of PL- $\Delta$ Taq to use short primers in PCR amplification. When long primers (57F and 732R) were used, the amplified product generated by PL- $\Delta$ Taq is ~50% of that by Sso7d- $\Delta$ Taq. When short primers (57F12 and 732R16) were used, the amplified product generated by PL- $\Delta$ Taq is 5 <20% of that by Sso7d- $\Delta$ Taq.

Table III. Comparison of the effect of primer length on PCR amplification by Sso7d- $\Delta$ Taq and Taq DNA polymerase.

polymerase	22 nt primer		15 nt primer		12 nt primer	
	Anneal @55°C	Anneal @63°C	Anneal @49°C	Anneal @54°C	Anneal @49°C	Anneal @54°C
Taq	14000	9000	5500	<500	1000	undetectable
Sso7d- $\Delta$ Taq	17000	13000	15000	5000	10000	3000
Sso7d- $\Delta$ Taq:Taq	1.2:1	1.4:1	2.7:1	>10:1	10:1	>10:1

10

Increased performance of fusion polymerases in PCR reactions

The increased stability and/or processivity of the fusion proteins of the invention provide increased efficiency in performing various modification reactions. For 15 example, polymerase fusion proteins can provide more efficient amplification in PCR reactions. Many factors influence the outcome of a PCR reaction, including primer specificity, efficiency of the polymerase, quality, quantity and GC-content of the template, length of the amplicon, *etc.* Examples 5-8 demonstrate that fusion proteins that include a double-stranded sequence-non-specific nucleic acid binding domain, *e.g.*, Sso7d, joined to a 20 thermostable polymerase or polymerase domain have several advantageous features over the unmodified enzyme in PCR applications.

Example 5. Sso7d fusion proteins exhibit a higher and broader salt-tolerance in PCR

The binding of polymerase to a primed DNA template is sensitive to the ionic 25 strength of the reaction buffer due to electrostatic interactions, which is stronger in low salt concentration and weaker in high. The presence of Sso7d in a fusion polymerase protein stabilizes the binding interaction of the polymerase to DNA template. This example demonstrates that Sso7d fusion proteins exhibit improved performance in PCR reactions containing elevated KCl concentrations.

30 Lambda DNA (2 pM) was used as a template in a PCR reactions with primers 57F and 732R. The concentration of KCl was varied from 10 mM to 150 mM, while all other

components of the reaction buffer were unchanged. The PCR reaction was carried out using a cycling program of 94°C for 3 min, 20 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec, followed by 72°C for 10 min. Upon completion of the reaction, 5 µl of the PCR reaction was removed and mixed with 195 µl of 1:400 dilution of PicoGreen in TE to 5 quantify the amounts of amplicon generated. The PCR reaction products were also analyzed in parallel on an agarose gel to verify that amplicons of expected length were generated (data not shown). The effects of KCl concentration on the PCR efficiency of Sso7d-ΔTaq versus that of ΔTaq, and Pfu-Sso7d versus Pfu are shown in Table IV. The unmodified enzymes, ΔTaq and Pfu, showed a preference for KCl concentration below 25 mM and 40 mM, 10 respectively, to maintain 80% of the maximum activity. In contrast, fusion proteins Sso7d-ΔTaq and Pfu-Sso7d maintain 80% of the maximum activity in 30-100 mM and 60-100 mM KCl, respectively. Thus, the Sso7d fusion proteins were more tolerant of elevated KCl concentration in comparison to their unmodified counter parts. This feature of the hybrid polymerase will potentially allow PCR amplification from low quality of DNA template, e.g., 15 DNA samples prepared from, but not limited to, blood, food, and plant sources.

**Table IV. Sso7d modification increases salt-tolerance of polymerase in PCR reaction**

Enzyme	Enzyme concentration	[KCl] for 80% activity
ΔTaq	20U/ml	<25 mM
Sso7d-ΔTaq	20U/ml	30-100 mM
Pfu	3 U/ml	<40 mM
Pfu-Sso7d	12U/ml* (equal molar)	60-100 mM

\* Pfu-Sso7d has a 4-fold higher specific activity than Pfu. The specific activity is defined as unit/mol of enzyme.

20

**Example 6. Sso7d fusion polymerases require shorter extension time in PCR**

The processivity of a polymerase directly effects the efficiency of the polymerization step. For example, a polymerase with low processivity dissociates more 25 frequently and requires more time to rebind to the primed-template, whereas a polymerase with high processivity requires fewer binding events to complete replication of the entire template. As demonstrated in Example 2, Sso7d fusion proteins have significantly higher processivity than their unmodified counterparts. Thus, the fusion proteins should be more efficient during the primer extension step of a PCR reaction. Here we provide examples 30 demonstrating that an Sso7d fusion polymerase requires a shorter extension time to amplify a large fragment during PCR compared to unmodified polymerases. In addition, we show that

a single enzyme fusion polymerase exhibits an enhanced ability to amplify large DNA fragments in a limited amount of time in comparison to an enzyme mixture (DyNAzyme EXT) currently used in the art for amplification of large fragments.

5 *Example 6-1. Sso7d fusion polymerases require shorter extension time in PCR*

Lambda DNA (2.25 pM) was used as a PCR template. Three pairs of primers L71F (5'-CCTGCTCTGCCGCTTCACGC-3') and L71R (5'-GCACAGCGGCTGGCTGAG GA-3'), L18015F (5'-TGACGGAGGATAACGCCAGCAG-3') and L23474R (5'-GAAAGACGA TGGGTCGCTAATACGC-3'), and L18015F (5'-TGACGGAGGATAAC 10 GCCAGCAG-3') and L29930R (5'-GGGGTTGGAGGTCAATGGGTC-3'), were used to amplify DNA fragments of the size of 0.9 kb, 5.5 kb and 11.9 kb, respectively. Each reaction contained 40 unit/ml of polymerase, where the unit was defined as described in Example 2, and 0.36 mM of each of the four dNTPs. The reaction buffer used for Pfu (from Stratagene) contained 20 mM Tris-HCl (pH 8.8), 2 mM MgSO<sub>4</sub>, 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1% 15 Triton X-100, and 0.1 mg/ml BSA. The reaction buffer for Pfu-Sso7d, Taq, and Sso7d-Taq was the above buffer with an additional 40 mM of KCl. Two cycling programs with a 1 min or a 5 min extension time were used for PCR amplification. Each cycling program was composed of 94°C for 20 sec, hot start at 80°C by the addition of the polymerase, 20 cycles of 94°C for 10 sec followed by 72°C for 1 or 5 min, and 72°C for 5 min. The results showed 20 that a Pfu-Sso7d fusion protein was able to amplify both the 1 kb and 5 kb fragments using a 1 min extension time, and was also able to amplify the 10 kb fragment using a 5 min extension time. In contrast, Pfu polymerase amplified only the 1 kb fragment using either a 1 min or a 5 min extension time. Similarly, the Sso7d-Taq fusion protein amplified the 1 kb fragment using a 1 min extension time, and both the 1 kb and 5 kb fragments with a 5 min 25 extension time, whereas Taq polymerase amplified only the 1 kb fragment with a 5 min extension time.

Thus, the presence of Sso7d in the fusion protein results in shorter extension times in PCR reactions compared to the unmodified protein.

30 *Example 6-2. Pfu-Sso7d fusion polymerase outperforms existing long PCR enzyme mixture*

Currently, PCR amplification of long DNA fragments requires the use of an enzyme mixture containing both a non-proofreading polymerase (e.g. Taq or DyNAzyme II) and a small amount of proofreading polymerase (e.g. Pfu or Deep Vent). We have compared a single fusion enzyme, Pfu-Sso7d, to one of the high performance, long PCR enzymes

DyNAzyme EXT (from Finnzymes) in long PCR, and demonstrated that Pfu-Sso7d outperforms DyNAzyme EXT, especially with limited extension time.

Lambda DNA (2.25 pM) was used as a PCR template. Four pairs of primers L71F (5'-CCTGCTCTGCCGCTTCACGC-3') and L71R (5'-GCACAGCGGCTGGCTGAG 5 GA-3'), L30350F (5'-CCTGCTCTGCCGCTTCACGC-3') and L35121R (5'-CACATGGTACAGCAAGCCTGGC-3'), L2089F (5'-CCCGTATCTGCTGGGA TACTGGC-3') and L7112R (5'-CAGCGGTGCTGACTGAATCATGG-3'), and L30350F (5'-CCTGCCTGCCGCTTCACGC-3') and L40547R (5'-CCAATACCCGTTCA TCGCGGC-3') were used to amplify DNA fragments of the size of 0.9 kb, 4.8 kb, 5.0 kb and 10 10.2 kb, respectively. Four concentrations (10 unit/ml, 20 unit/ml, 40 unit/ml and 80 unit/ml) of Pfu-Sso7d were used, and two concentrations (20 unit/ml and 40 unit/ml) of DyNAzyme EXT were used. Each reaction contained 0.36 mM of each of the four dNTPs. The reaction buffer for Pfu-Sso7d was as described in Example 6-1. The reaction buffer for DyNAzyme EXT contained 20 mM Tris (pH 9.0), 2 mM MgCl<sub>2</sub>, 15 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and 0.1 % Triton X-15 100 (provided by Finnzymes). All reaction components were first mixed on ice, and the reactions were initiated by placing the sample plates into a thermal cycler (MJ Research) preheated to over 90°C. The PCR cycling program consists of 95°C for 20 sec, 20 cycles of 94°C for 10 sec and 70°C for 1 or 1.5 min, and 1 cycle of 72°C for 10 min.

As shown in Figure 3, a 1 min extension time using Pfu-Sso7d generated 20 significant amounts of the 0.9 kb product in the presence of 10, 20, 40 and 80 unit/ml of polymerase. The 4.8 kb and 5.0 kb products were also produced, although at a lower level, in the presence of 40 and 80 unit/ml of polymerase. Using a 1.5 min extension, the 4.8 kb and 5.0 kb products were generated with 10 unit/ml or higher Pfu-Sso7d, and the 10.2 kb fragment was produced in a significant amount with 40 and 80 unit/ml of Pfu-Sso7d. In 25 contrast, when DyNAzyme EXT was used, only the 1kb and 4.8 kb products were generated using 1.5 min extension time in the presence of 40 unit/ml of polymerase, and no 10 kb product was detected.

Thus, the fusion polymerase Pfu-Sso7d is notably more efficient as a single enzyme than an enzyme mixture such as DyNAzyme EXT in long PCR.

30

#### Example 7. Sso7d fusion proteins are more sensitive in PCR amplification

This example demonstrates that an Sso7d fusion polymerase can amplify a target that is present at a lower copy number compared to the unmodified polymerases. Plasmid DNA was used as a PCR template with T3 and T7 as the primers, which amplify a

500 bp fragment. The amount of plasmid DNA was varied so that the number of copies of DNA template present in the PCR reaction ranged from  $10^8$  to 1. The cycling program was 94°C for 3 min, 25 or 35 cycles of 96°C for 1 sec, 50°C for 15 sec, and 68°C for 30 sec, followed by 1 cycle at 68°C for 5 min. For template copy numbers from  $10^4$  to  $10^8$  (per 25 µl reaction), 25 cycles of amplification were performed; for template copy numbers from 1 to 10<sup>4</sup> (per 25 µl reaction), 35 cycles of amplification were performed.

10 The Sso7d fusion polymerase was compared to the unmodified polymerase in the requirements for minimum copies of template for efficient amplification. As shown in Table V, Pfu-Sso7d is significantly more sensitive than Pfu in its ability to amplify a low copy number of DNA template, showing that fusion polymerase of the invention can increase the sensitivity of PCR reactions by as much as five orders of magnitude.

Table V. Sso7d fusion protein can amplify using a lower number of copies of DNA template

Enzymes	Minimum copies for amplification
Pfu	$>10^7$
Pfu-Sso7d	$10^2$

15

**Example 8. Sso7d fusion polymerases maintain high specificity in a PCR reaction**

As shown in Example 3, Sso7d-ΔTaq fusion protein stabilizes primer-template interactions, as reflected by its ability to allow higher annealing temperature and/or shorter primers in PCR amplification. To assess whether this property of the fusion protein would 20 result in nonspecific amplification in PCR, a complex DNA template (e.g. human genomic DNA) was used as the target template. The following two examples demonstrate that the specificity of amplification achieved using Pfu-Sso7d is no less than that Taq, the most commonly used PCR enzyme.

25 *Example 8-1. Amplification of a gender-specific marker from human DNA using Pfu-Sso7d*

Human female or male type DNA (concentration, 1 fM) from placenta or chorionic tissue (from Sigma) was used as the template. Primers H-Amelo-Y (5'-CCACCTCATCCTGG GCACC-3') and H-Amelo-YR (5'-GCTTGAGGCCAACCATCA GAGC-3') were used to amplify a 212 bp amplicon from X chromosome and a 218 bp 30 amplicon from Y chromosome. A single 212 bp fragment should be amplified from female typed DNA, whereas three fragments (212 bp, 218 bp, and the 212 bp/218 bp heterozygote)

were expected from male typed DNA. Each reaction contained 20 unit/ml of polymerase and 0.36 mM of each of the four dNTPs. The reaction buffer for Taq included 10 mM Tris (pH 8.8), 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 0.1% Triton X-100 (provided by Amersham). The reaction buffer for Pfu-Sso7d contains was performed using DyNAzyme EXT buffer (see 5 Example 6-2) with an additional 40 mM KCl. All reaction components were mixed on ice, and the reaction was initiated by placing the plates into a thermal cycler preheated to above 65°C. The cycling program consisted of 95°C for 2 min, 30 cycles of 94°C for 5 sec, 64°C for 10 sec, and 72°C for 10 sec, followed by 1 cycle of 7 min at 72°C. Specific amplicons of expected sizes were amplified by both Pfu-Sso7d and Taq polymerase.

10

*Example 8-2. Amplification of β-globin gene from human DNA using Pfu-Sso7d*

Human DNA (1 fM) from placenta or chorionic tissue (from Sigma) was used as the template. Three pairs of primers, Bglbn536F (5'-GGTGGCCAATCTA 15 CTCCCAGG-3') and Bglbn536R (5'-GCTCACTCAGTGTGGCAAAG-3'), Bglbn536F and Bglbn1083R, and Bglbn536F and Bglbn1408R (5'-GATTAGCAAAAGGGCCTAGCTTGG-3') were used to amplify DNA fragments of the size of 0.5, 1.1 and 1.4 kb, respectively. Each reaction contained 20 unit/ml of polymerase and 0.36 mM of each of the four dNTPs. The reaction buffers for Taq and Pfu-Sso7d were as described in Example 8-1. All reaction components were first mixed on ice, and the reactions were initiated by placing the plates into 20 a thermal cycler preheated to above 65°C. The cycling program consists of 95°C for 2 min, 30 cycles of 94°C for 45 sec, 64°C for 45 sec, and 72°C for 1 min, followed by 1 cycle of 7 min at 72°C. With each of the three pair of primers used, an amplified product of the expected size was produced using Pfu-Sso7d. These results show that the specificity of amplification achieved by using Pfu-Sso7d is equal or better than that with Taq polymerase.

25

**SEQUENCE LISTING****SEQ ID NO:1 Synthetic Sso7d gene**

GCAACCGTAAAGTTCAAGTACAAAGGCGAAGAAAAAGAGGTAGACATCTCAA  
 5 GATCAAGAAAGTATGGCGTGTGGCAAGATGATCTCCTCACCTACGACGAGGG  
 CGGTGGCAAGACCGGCCGTGGTGCCTAAGCGAAAAGGACGCGCCGAAGGAGC  
 TGCTGCAGATGCTGGAGAAG  
 CAGAAAAAG

**10 SEQ ID NO:2 The amino acid sequence of Sso7d.**

ATVKFKYKGEEKEVDISKIKKVVWRVGKMSFTYDEGGGKTGRGA  
 VSEKDAPKELLQ  
 MLEKQKK

**SEQ ID NO:3 The DNA sequence encoding the Sso7d-ΔTaq fusion protein**

15 ATGATTACGAATTCGAGCGCAACCGTAAAGTTCAAGTACAAAGGCGAAGAAAAAA  
 GAGGTAGACATCTCCAAGATCAAGAAAGTATGGCGTGTGGCAAGATGATCTCC  
 TTCACCTACGACGAGGGCGGTGGCAAGACCGGCCGTGGTGCCTAAGCGAAAAG  
 GACGCGCCGAAGGAGCTGCTGCAGATGCTGGAGAAGCAGAAAAAGGGCGCGG  
 TGTCACTAGTCCAAGGCCTGGAGGAGGCCCTGGCCCCCGCCGGAAGGGGCC  
 20 TTCGTGGCTTGTGCTTCCCGCAAGGAGCCATGTGGGCCGATCTCTGGCCCT  
 GGCGCCGCCAGGGGGGCCGGTCCACCGGGCCCCGAGCCTTATAAAGCCCT  
 CAGGGACCTGAAGGAGGCGCGGGGCTCTCGCAAAGACCTGAGCGTTCTGGC  
 CCTGAGGGAAGGCCTTGGCCTCCGCCGGCACGACCCATGCTCTCGCCTAC  
 CTCCTGGACCCTTCCAACACCACCCCGAGGGGGTGGCCGGCGTACGGCGGG  
 25 GAGTGGACGGAGGAGGCGGGGGAGCGGGCCCTTCCGAGAGGCTCTCGCC  
 AACCTGTGGGGGAGGCTTGAGGGGGAGGAGAGGCTCTTGGCTTACCGGGAG  
 GTGGAGAGGCCCTTCCGCTGTCCCTGGCCCACATGGAGGCCACGGGGTGC  
 CTGGACGTGGCCTATCTCAGGGCCTTGGAGGTGGCCGAGGAGATGCC  
 GCCTCGAGGCCGAGGTCTTCCGCTGGCCGGCACCCCTCAACCTCAACTCCG  
 30 GGACCAGCTGGAAAGGGCTCTTGACGAGCTAGGGCTCCGCCATGGCAA  
 GACGGAGAAGACCGCAAGCGCTCCACCAGCGCCGCTGGAGGCCCTCG  
 CGAGGCCACCCATCGTGGAGAAGATCCTGCAGTACCGGGAGCTACCAAGCT  
 GAAGAGCACCTACATTGACCCCTGCCGGACCTCATCCACCCAGGACGGCG  
 CCTCCACACCCGCTCAACCAGACGGCACGGCACGGCAGGCTAAGTAGCTC

CGATCCAACCTCCAGAACATCCCCGTCCGCACCCGCTTGGCAGAGGATCCGC  
 CGGGCCTTCATCGCCGAGGAGGGTGGCTATTGGTGGCCCTGGACTATAGCCAG  
 ATAGAGCTCAGGGTGTGGCCCACCTCTCCGGCGACGAGAACCTGATCCGGTCT  
 TCCAGGAGGGCGGGACATCCACACGGAGACCGCCAGCTGGATGTTGGCGTCC  
 5 CCCGGAGGCCGTGGACCCCTGATGCGCCGGCGCCAAGACCATCAACTTCG  
 GGGTCCTCTACGGCATGTCGGCCCACCGCCTCTCCCAGGAGCTAGCCATCCCTTA  
 CGAGGAGGCCAGGCCTTCATTGAGCGCTACTTCAGAGCTCCCCAAGGTGCGG  
 GCCTGGATTGAGAAGACCCCTGGAGGAGGGCAGGAGGCGGGGTACGTGGAGAC  
 CCTCTCGGCCGCCGCGCTACGTGCCAGACCTAGAGGCCGGGTGAAGAGCGT  
 10 CGGGAGGCAGGCCGAGCGCATGGCCTCAACATGCCGTCCAGGGCACCGCCGC  
 CGACCTCATGAAGCTGGCTATGGTGAAGCTCTCCCCAGGCTGGAGGAAATGGG  
 GCCCAGGATGCTCCTCAGGTCCACGACGAGCTGGCCTCGAGGCCAAAAGA  
 GAGGGCGGAGGCCGTGGCCCGTGGCCAAGGAGGTATGGAGGGGTATCC  
 CCTGGCCGTGCCCTGGAGGTGGAGGTGGAGGTAGGGAGGACTGGCTCTCCGC  
 15 CAAGGAGGGCATTGATGGCCCGGCGGAGGCAGGCATCATCATCATCATCATTA  
 A

**SEQ ID NO:4 The amino acid sequence of Sso7d-ΔTaq fusion protein**

MITNSSATVKFKYKGEEKEVDISKIKKVVWRVGKMSFTYDEGGGKTGRGAVSEKDA  
 20 PKELLQMELQKKGGGVTPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAA  
 ARGGRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDP  
 SNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLS  
 AVLAHMEATGVRLDVAYLRLALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLF  
 DELGLPAIGKTEKTGKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIH  
 25 PRTGRLHTRFNQTATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYS  
 QIELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAKTINFGV  
 LYGMASAHRLSQELAIPYEEAQAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGR  
 RYVPDLEARVKSvreAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLL  
 QVHDELVLEAPKERAEEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKEGIDGR  
 30 GGGGHHHHHH

**SEQ ID NO:5 The DNA sequence encoding the Sso7d-Taq fusion protein**

ATGATTACGAATTGAGCGCAACCGTAAAGTTCAAGTACAAAGGCGAAGAAAAAA

GAGGTAGACATCTCCAAGATCAAGAAAGTATGGCGTGTGGCAAGATGATCTCC  
TTCACCTACGACGAGGGCGGTGGCAAGACCGGCCGTGGTGCCTGAAGCGAAAAG  
GACGCCGAAGGAGCTGCTGCAGATGCTGGAGAAGCAGAAAAAGGGCGCGG  
TGTCACTAGTGGATGCTGCCCTCTTGAGCCAAGGGCGGGTCCTCCTGGT  
5 GACGCCACCACCTGGCCTACCGCACCTCCACGCCCTGAAGGGCCTCACCA  
GCCGGGGGGAGCCGGTGCAGGCCTACGGCTGCCAAGAGCCTCCTCAAGG  
CCCTCAAGGAGGACGGGACGCCGGTACGGGTCTTGA  
10 AGGACTTTCCCCGGCAACTGCCCTCATCAAGGAGCTGGTGGACCTCCTGGGCT  
GGCGGCCTCGAGGTCCCAGGCTACGAGGCAGACGTCCCTGGCCAGCCTGGC  
CAAGAAGGCGAAAAGGAGGGTACGAGGTCCGCATCCTCACCGCCGACAAAG  
ACCTTACCAAGCTCCTTCCGACCGCATCCACGTCCACCCGAGGGTACCT  
CATCACCCGGCCTGGCTTGGAAAAGTACGGCTGAGGCCGACCAGTGGC  
CGACTACCGGCCCTGACCGGGACGAGTCCGACAACCTCCGGGTCAAGGG  
15 CATCGGGAGAAGACGGCGAGGAAGCTCTGGAGGAGTGGGGAGCCTGGAAG  
CCCTCCTCAAGAACCTGGACCGGCTGAAGCCGCCATCCGGAGAAGATCCTGG  
CCCACATGGACGATCTGAAGCTCTCCTGGACCTGGCCAAGGTGCGCACCGACCT  
GCCCTGGAGGTGGACTCGCAAAAGGCGGGAGCCGACCGGGAGAGGCTTAG  
GGCCTTCTGGAGAGGCTTGAGTTGGCAGCCTCCACGAGTTGGCCTCTG  
20 GAAAGCCCCAAGGCCTGGAGGAGGCCCTGGCCCCCGCCGGAAAGGGCCTTC  
GTGGCTTGTGCTTCCGCAAGGAGCCATGTGGCCGATCTCTGGCCCTGG  
CCGCCGCCAGGGGGGCCGGTCCACGGGCCCCGAGCCTATAAGCCCTCA  
GGGACCTGAAGGAGGCGCGGGCTCTGCCAAAGACCTGAGCGTTCTGGCCC  
TGAGGGAAGGCCCTGGCCTCCGCCCGACGACCCATGCTCCTGCCCTACCT  
25 CCTGGACCTCCAACACCACCCCCGAGGGGTGGCCCCGGCTACGGCGGG  
GTGGACGGAGGAGGCGGGGAGCGGGCCGCCCTTCCGAGAGGCTTCGCCAA  
CCTGTGGGGAGGTCTTGAGGGGAGGAGAGGCTCTTGGCTTACGGGAGGT  
GGAGAGGCCCTTCCGCTGTCCCTGGCCCACATGGAGGCCACGGGGTGCCT  
GGACGTGGCCTATCTCAGGCCCTGTCCCTGGAGGTGGCCGAGGAGATCGCCCG  
30 CCTCGAGGCCGAGGTCTCCGCCCTGGCCGCCACCCCTCAACCTCAACTCCGG  
GACCAGCTGAAAGGGCCTCTTGACGAGCTAGGGCTCCGCCATCGCAAG  
ACGGAGAAGACCGCAAGCGCTCCACCGCGCCGCGTCTGGAGGCCCTCCGC  
GAGGCCACCCATCGTGGAGAAGATCCTGCAGTACCGGGAGCTACCAAGCTG  
AAGAGCACCTACATTGACCCCTGCCGGACCTCATCCACCCAGGACGGCCGCC

TCCACACCCGCTCAACCAGACGCCACGCCACGGCAGGCTAAGTAGCTCCG  
 ATCCCAACCTCCAGAACATCCCCGTCCGCACCCGCTGGCAGAGGATCCGCCG  
 GGCCTTCATGCCGAGGAGGGTGGCTATTGGTGGCCCTGGACTATAGCCAGAT  
 AGAGCTCAGGGTGCTGGCCCACCTCTCCGGCAGCAGAACCTGATCCGGTCTC  
 5 CAGGAGGGCGGGACATCCACACGGAGACCGCCAGCTGGATGTTGGCGTCCCC  
 CGGGAGGCCGTGGACCCCTGATGCCCGGGCGGCCAAGACCATCAACTCGGG  
 GTCCTCTACGGCATGTCGGCCCACCGCCTCTCCCAGGAGCTAGCCATCCCTACG  
 AGGAGGCCAGGCCTCATTGAGCGCTACTTCAGAGCTTCCCAAGGTGCGGGC  
 CTGGATTGAGAAGACCCCTGGAGGAGGGCAGGAGGCAGGGTACGTGGAGACCC  
 10 TCTTCGGCCGCCGCTACGTGCCAGACCTAGAGGCCGGGTGAAGAGCGTGC  
 GGGAGGCCGAGCGCATGGCCTCAACATGCCGTCCAGGGCACCGCCGCCG  
 ACCTCATGAAGCTGGCTATGGTGAAGCTCTCCCCAGGCTGGAGGAAATGGGGG  
 CCAGGATGCTCCTCAGGTCCACGACGAGCTGGCCTCGAGGCCAAAAGAGA  
 GGGCGGAGGCCGTGGCCGGCTGGCCAAGGAGGTATGGAGGGGGTATCCCC  
 15 TGGCGTGCCTGGAGGTGGAGGTGGGATAGGGAGGACTGGCTCTCCGCCA  
 AGGAGGGCATTGATGCCCGCGAGGCGGGCATCATCATCATCATCATTAA

**SEQ ID NO:6 The amino acid sequence of Sso7d-Taq fusion protein.**

MITNSSATVKFKYKGEKEVDISKIKKVVWRVGKMSFTYDEGGKTRGA  
 20 SEKDA  
 PKELLQMILEKQKKGGVTSGMLPLFEPKGRVLLVDGHHLAYRTFH  
 ALKGLTTSRGE  
 PVQAVYGF  
 AAKSLLKALKEDGDAVIVVFD  
 AKAPSFRHEAYGGYKAGR  
 APTPEDFPRQ  
 LALIKELVDLLGLARLE  
 VPGYEADDV  
 LASLAKKAEKE  
 GYEVRILTADK  
 DLYQLLSDR  
 IHVLHPEGYL  
 ITPAWLWE  
 KYGLRPDQWADYR  
 ALTGDES  
 DNLPGVKG  
 IGEKTARK  
 EEWGSLE  
 ALLKNLDRLK  
 PAIREK  
 ILAHM  
 DDLKLSW  
 DLA  
 KVRT  
 DLP  
 LEVDF  
 AKRREP  
 25 DRERLRAFLER  
 LEFGSLLHEF  
 GLLESPK  
 ALEEAP  
 WPPP  
 PEGAF  
 VGF  
 VLSR  
 KEP  
 MWADL  
 LALAAARGGR  
 VHRAPE  
 PYKALRDL  
 KEARG  
 LLA  
 KDL  
 SVL  
 ALREG  
 LGL  
 PPG  
 DDP  
 MLLA  
 YLL  
 DPS  
 NTT  
 PEG  
 VARRY  
 GGE  
 WTEE  
 AGERA  
 AAL  
 SERL  
 FANL  
 WGR  
 LE  
 GER  
 LLW  
 LY  
 REV  
 ERPL  
 SAV  
 LAH  
 MEAT  
 GVR  
 LDV  
 AYL  
 RALS  
 LEVA  
 E  
 E  
 IAR  
 LEA  
 EV  
 FRL  
 A  
 GHP  
 FN  
 LNS  
 RDQL  
 ERV  
 LF  
 DEL  
 GLP  
 AIG  
 K  
 TEKT  
 GKR  
 STS  
 AAV  
 LE  
 AL  
 RE  
 A  
 HPI  
 V  
 E  
 K  
 ILQ  
 Y  
 RE  
 L  
 T  
 KLK  
 STY  
 IDPL  
 30 PDLIHP  
 RTGRLH  
 TRFN  
 QTAT  
 ATG  
 RLSS  
 SDPN  
 LQ  
 NIP  
 VRTPL  
 GQR  
 IRRA  
 FIA  
 E  
 EG  
 WLL  
 VA  
 LDY  
 SQIEL  
 RVLA  
 HLS  
 GDE  
 N  
 LIR  
 VF  
 QE  
 GRD  
 I  
 H  
 T  
 E  
 T  
 A  
 SW  
 MFG  
 V  
 PRE  
 A  
 VD  
 PL  
 M  
 RRA  
 AKTI  
 NFG  
 VLY  
 GMSA  
 HRLS  
 Q  
 E  
 LA  
 I  
 PY  
 Y  
 E  
 E  
 A  
 QAF  
 I  
 ERY  
 F  
 QSF  
 PK  
 V  
 R  
 A  
 W  
 I  
 E  
 K  
 T  
 L  
 E  
 E  
 G  
 R  
 R  
 R  
 GY  
 V  
 E  
 T  
 L  
 FG  
 R  
 R  
 R  
 Y  
 V  
 P  
 D  
 L  
 E  
 A  
 R  
 V  
 K  
 S  
 V  
 R  
 E  
 A  
 A  
 E  
 R  
 M  
 A  
 F  
 N  
 M  
 P  
 V  
 Q  
 G  
 T  
 A  
 A  
 D  
 L  
 M  
 K  
 L  
 A  
 M  
 V  
 K  
 L  
 F  
 P  
 R  
 L  
 E  
 E  
 M  
 G  
 A

RMLLQVHDELVLEAPKERAEEAVRLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE  
GIDGRGGGGHHHHHH

**SEQ ID NO:7 The DNA sequence encoding the Pfu-Sso7d fusion protein**

5 ATGATTITAGATGTGGATTACATAACTGAAGAAGGAAAACCTGTTATTAGGCTAT  
TCAAAAAAGAGAACGGAAAATTAAAGATAGAGCATGATAGAACTTTAGACCAT  
ACATTACGCTCTCTCAGGGATGATTCAAAGATTGAAGAAGTTAAGAAAATAAC  
GGGGAAAGGCATGGAAAGATTGTGAGAATTGTTGATGTAGAGAAGGTTGAGAA  
AAAGTTCTCGGCAAGCCTATTACCGTGTGGAAACTTATTGGAACATCCCCAA  
10 GATGTTCCCACATTAGAGAAAAAGTTAGAGAACATCCAGCAGTTGTGGACATCT  
TCGAATACGATATTCCATTGCAAAGAGATAACCTCATCGACAAAGGCCAATACC  
AATGGAGGGGAAGAACAGAGCTAAAGATTCTGCCTCGATATAGAAACCTCTA  
TCACGAAGGAGAACAGAGTTGGAAAAGGCCAATTATAATGATTAGTTATGCAGA  
TGAAAATGAAGCAAAGGTGATTACTGGAAAAACATAGATCTCCATACGTTGA  
15 GGTGTTATCAAGCGAGAGAGAGATGATAAAGAGATTCTCAGGATTATCAGGGA  
GAAGGATCCTGACATTATAGTTACTTATAATGGAGACTCATTGACTTCCATAT  
TTAGCGAAAAGGGCAGAAAAACTTGGGATTAAATTAAACCATTGGAAGAGATGGA  
AGCGAGCCAAGATGCAGAGAACAGCGATATGACGGCTGTAGAAGTCAAGGG  
AAGAATACATTCGACTTGTATCATGTAATAACAAGGACAATAAATCTCCAAACA  
20 TACACACTAGAGGCTGTATATGAAGCAATTGGAAAGCCAAGGGAGAAGGTA  
TACGCCGACGAGATAGCAAAAGCCTGGAAAGTGGAGAGAACCTTGAGAGAGTT  
GCCAAATACTCGATGGAAGATGCAAAGGCAACTTATGAACTCGGGAAAGAAC  
CTTCCAATGGAAATTCAAGCTTCAAGATTAGTTGGACAACCTTATGGATGTT  
CAAGGTCAAGCACAGGGAACCTGTAGAGTGGTTCTTACTTAGGAAAGCCTACG  
25 AAAGAAACGAAGTAGCTCCAAACAAGCCAAGTGAAGAGGGAGTATCAAAGAAGG  
CTCAGGGAGAGCTACACAGGTGGATTGTTAAAGAGGCCAGAAAAGGGTTGTGG  
GAAAACATAGTATAACCTAGATTAGAGCCCTATATCCCTCGATTATAATTACCC  
ACAATGTTCTCCGATACTCTAAATCTGAGGGATGCAAGAACATGATATCGC  
TCCTCAAGTAGGCCACAAGTCTGCAAGGACATCCCTGGTTTATAACCAAGTCTC  
30 TTGGGACATTGTTAGAGGAAAGACAAAAGATTAAGACAAAAATGAAGGAAACT  
CAAGATCCTATAGAAAAAAACTCCTGACTATAGACAAAAAGCGATAAAACTC  
TTAGCAAATTCTTCTACGGATATTATGGCTATGCAAAAGCAAGATGGTACTGTA  
AGGAGTGTGCTGAGAGCGTTACTGCCTGGGGAAAGAAAGTACATCGAGTTAGTAT  
GGAAGGAGCTCGAAGAAAAGTTGGATTAAAGTCCTCTACATTGACACTGATG

GTCTCTATGCAACTATCCCAGGAGGAGAAAGTGAGGAAATAAGAAAAAGGCTC  
 TAGAATTGTAAAATACATAAATTCAAAGCTCCCTGGACTGCTAGAGCTTGAATA  
 TGAAGGGTTTATAAGAGGGATTCTCGTTACGAAGAAGAGGTATGCAGTAAT  
 AGATGAAGAAGGAAAAGTCATTACTCGTGGTTAGAGATAGTTAGGAGAGATTG  
 5 GAGTGAAATTGCAAAAGAAACTCAAGCTAGAGTTGGAGACAATACTAAAACA  
 CGGAGATGTTGAAGAAGCTGTGAGAATAGTAAAAGAAGTAATACAAAAGCTTGC  
 CAATTATGAAATTCCACCAAGAGAAGCTCGCAATATATGAGCAGATAACAAGACC  
 ATTACATGAGTATAAGGCGATAGGTCCCTCACGTAGCTGTTGCAAAGAAAAGCT  
 GCTAAAGGAGTTAAAATAAGCCAGGAATGGAATTGGATACATAGTACTTAGA  
 10 GGCGATGGTCCAATTAGCAATAGGGCAATTCTAGCTGAGGAATACGATCCAAA  
 AAGCACAAGTATGACGCAGAATATTACATTGAGAACCAGGTTCTCAGCGGT  
 CTTAGGATATTGGAGGGATTGGATACAGAAAGGAAGACCTCAGATACCAAAAG  
 ACAAGACAAGTCGGCCTAACCTCCTGGCTAACATTAAAAAATCCGGTACCGGC  
 GGTGGCGGTGCAACCGTAAAGTTCAAGTACAAAGGCGAAGAAAAGAGGTAGA  
 15 CATCTCCAAGATCAAGAAAGTATGGCGTGTGGCAAGATGATCTCCTCACCTAC  
 GACGAGGGCGGTGGCAAGACCGGCGTGGTGCCTAAGCGAAAAGGACGCGCC  
 GAAGGAGCTGCTGCAGATGCTGGAGAAGCAGAAAAAGTGA

**SEQ ID NO:8 The amino acid sequence of the Pfu-Sso7d fusion protein**

20 MILDVDYITEEGKPVIRLFKKENGKFKIEHDRTRPYIYALLRDDSKIEEVKKITGERH  
 GKIVRIVDVEKVEKKFLGKPITVWKLYLEHPQDVPTIREKVREHPAVVDIFEYDIPFA  
 KRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGKGPIIMISYADENEAKVITWKNID  
 LPYVEVVSSEREMIKRFLRIIREKDPDITVTYNGDSFDFPYLAKRAEKGKLTIGRDGS  
 EPKMQRIGDMTAVEVKGRIFDLYHVITRTINLPTYTLEAVYEAIKGPKKEKVYADEI  
 25 AKAWESENLERVAKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVRSSTGN  
 LVEWFLLRKAAYERNEVAPNKPSEEYQRRLRESYTGGFVKEPEKGLWENIVYLDFR  
 ALYPSIITHNVSPDTLNLEGCKNYDIAPQVGHKFCKDIPGFIPSLLGHLEERQKIKTK  
 MKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKECAESVTAWGRKYIE  
 LVWKELEEKFGFKVLYIDTDGLYATIPGGESEEIKKKALEFVKYINSKLPGLLELEYE  
 30 GFYKRGFFVTKKRYAVIDEEGKVITRGLIEVRRDWSEIAKETQARVLETILKHGDVEE  
 AVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKKLAAGVKIKPG  
 MVIGYIVLRGDGPISNRAILAEYDPKKHKYDAEYYIENQVLPALRILEGFGYRKED  
 LRYQKTRQVGLTSWLNKKSGTGGGGATVKFKYKGEEKEVDISKIKKVVWRVGKMIS  
 FTYDEGGGKTGRGAVSEKDAPKELLQMLEKQKK

**SEQ ID NO:9 The DNA sequence encoding the Sac7d-ΔTaq fusion protein**

ATGATTACGAATTCGACGGTGAAGGTAAAGTTCAAGTATAAGGGTGAAGAGAGAAA  
GAAGTAGACACTCAAAGATAAAAGAAGGTTGGAGAGTAGGCAAAATGGTGTCC  
5 TTTACCTATGACGACAATGGTAAGACAGGTAGAGGAGCTGTAAGCGAGAAAGAT  
GCTCCAAAAGAATTATTAGACATGTTAGCAAGAGCAGAAAGAGAGAAGAAAGG  
CGGCGGTGTCAGTCCCAAGGCCCTGGAGGAGGCCCTGGCCCCCGCCGA  
AGGGGCCCTCGTGGCTTGTGCTTCCGCAAGGAGCCATGTGGCCGATCTT  
CTGGCCCTGGCCGCCGCCAGGGGGGCCGGTCCACCGGGCCCCGAGCCTTAT  
10 AAAGCCCTCAGGGACCTGAAGGAGGCGCGGGGCTCTCGCCAAAGACCTGAGC  
GTTCTGGCCCTGAGGGAAAGGCCTTGGCCTCCGCCCGACGACCCATGCTCC  
TCGCCTACCTCCTGGACCCCTCCAACACACCACCCCGAGGGGGTGGCCCGCGCTA  
CGGCGGGAGTGGACGGAGGAGGCGGGGAGCGGGCCGCCCTTCCGAGAGGC  
TCTTCGCCAACCTGTGGGGAGGCTTGAGGGGGAGGAGAGGCTCCTTGGCTTA  
15 CCGGGAGGTGGAGAGGCCCTTCCGCTGTCCTGGCCCACATGGAGGCCACGGG  
GGTGCCTGGACGTGGCCTATCTCAGGGCCTGTCCTGGAGGTGGCCGAGGA  
GATCGCCCGCCTCGAGGCCGGTCTCCGCTGGCCGCCACCCCTAACCTCA  
ACTCCGGGACCAGCTGGAAAGGGCCTCTTGACGAGCTAGGGCTCCGCCAT  
CGGCAAGACGGAGAAGACCGCAAGCGCTCCACAGCGCCGCCGTGGAGGC  
20 CCTCCGCGAGGCCACCCATCGTGGAGAAGATCCTGCAGTACCGGAGCTCAC  
CAAGCTGAAGAGCACCTACATTGACCCCTGCCGGACCTCATCCACCCAGGACG  
GGCCGCCTCCACACCCGCTTCAACCAGACGCCACGCCACGGCAGGCTAAGT  
AGCTCCGATCCAACCTCCAGAACATCCCCGTCCGCACCCGCTGGCAGAGGA  
TCCGCCGGCCTTCATGCCGAGGAGGGTGGCTATTGGTGGCCCTGGACTATAG  
25 CCAGATAGAGCTCAGGGTGTGGCCACCTCTCCGGCAGAGAACCTGATCCG  
GGTCTTCCAGGAGGGCGGGACATCCACACGGAGACCGCCAGCTGGATGTCGG  
CGTCCCCCGGGAGGCCGTGGACCCCTGATGCCGCCGGGCCAACGACCATCAA  
CTTCGGGGCCTCTACGGCATGTCGGCCACCGCCTCTCCAGGAGCTAGCCATC  
CCTTACGAGGAGGCCAGGCCTTCAATTGAGCGCTACTTCAGAGCTCCCCAAGG  
30 TGCGGGCCTGGATTGAGAACCCCTGGAGGAGGGCAGGAGGCGGGTACGTG  
GAGACCCCTTCGGCCGCCGCGCTACGTGCCAGACCTAGAGGCCGGGTGAAG  
AGCGTGGGGAGGCCGAGCGCATGGCCTCAACATGCCGTCCAGGGCACC  
GCCGCCGACCTCATGAAGCTGGCTATGGTGAAGCTCTCCCCAGGCTGGAGGAA

ATGGGGGCCAGGATGCTCCTCAGGTCCACGACGAGCTGGTCCTCGAGGCCCA  
 AAAGAGAGGGCGGAGGCCGTGGCCCGGCTGCCAAGGAGGTATGGAGGGGGT  
 GTATCCCCTGGCCGTGCCCTGGAGGTGGAGGTGGGGATAGGGGAGGACTGGCT  
 CTCCGCCAAGGAGGGCATTGATGGCCGCGCGGAGGCAGGCATCATCATCA

5 TCATTA

**SEQ ID NO:10 The amino acid sequence of the Sac7d- $\Delta$ Taq fusion protein**

MTNSTVKVFKYKGEKEVDTISKIKVWRVGKMSFTYDDNGKTGRGAVSEKDA  
 PKELLDMLARAEREKKGGVTSPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLAL  
 10 AAARGGRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLL  
 DPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERP  
 LSAVLAHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLSRDQLERV  
 LFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLI  
 HPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDY  
 15 SQIELRVLAHLSDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAKTINFG  
 VLYGMSAHLSQELAIPYEEAQAFIERYFQSFPKVRAWIEKTLEEGRRGYVETLFGR  
 RRYVPDLEARVKSvreAAERMAFNMPVQGTAADLMKLMVKLFPRLLEEMGARML  
 LQVHDELVLEAPKERAEEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKEGIDG  
 RGGGGHHHHHH

20

**SEQ ID NO:11 The DNA sequence encoding the PL- $\Delta$ Taq fusion protein**

ATGATTACGAATTCGAAGAAAAAGAAAAAGAAAAAGCGTAAGAACGCAAAAA  
 GAAAAAGAAAGCGCGGTGTCACTAGTGGCGCAACCGTAAAGTTCAAGTACAA  
 AGCGAAGAAAAAGAGGTAGACATCTCCAAGATCAAGAAAGTATGGCGTGTGG  
 25 GCAAGATGATCTCCTCACCTACGACGAGGGCGGTGGCAAGACCGGCCGTGGTGC  
 CGGTAAGCGAAAAGGACGCGCCGAAGGAGCTGCTGCAGATGCTGGAGAACAG  
 AAAAAGGGCGCGGTGTCACCAGTCCAAGGCCCTGGAGGAGGCCCTGGCC  
 CCGCCGGAAGGGCCTCGTGGCTTGTGCTTCCCGCAAGGAGGCCATGTGGG  
 CCGATCTCTGCCCTGGCCGCCAGGGGGCCGGTCCACCGGGCCCC  
 30 AGCCTTATAAAGCCCTCAGGGACCTGAAGGAGGCGGGGGCTCTCGCCAAAG  
 ACCTGAGCGTTCTGCCCTGAGGGAGGCCTGGCCTCCGCCGGCGACGACCC  
 CATGCTCCTCGCCTACCTCCTGGACCCTCCAACACCACCCCGAGGGGGTGGCC  
 CGGCGCTACGGCGGGAGTGGACGGAGGAGGCGGGGGAGCGGGCCGCCCTTCC

GAGAGGCTCTCGCCAACCTGTGGGGAGGCTTGAGGGGAGGAGAGGCTCCTT  
 TGGCTTACCGGGAGGTGGAGAGGCCCTTCCGCTGTCCTGGCCCACATGGAGG  
 CCACGGGGTGCCTGGACGTGGCTATCTCAGGGCCTGTCCTGGAGGTGGC  
 CGAGGAGATCGCCCGCCTCGAGGCCGAGGTCTCCGCCTGGCCGCCACCCCTC  
 5 AACCTCAACTCCCAGGACAGCTGGAAAGGGCCTCTTGACGAGCTAGGGCTTC  
 CCGCCATCGGCAAGACGGAGAAGACCGCAAGCGCTCCACCAGCGCCGCCGTCC  
 TGGAGGCCCTCCGCGAGGCCACCCATCGTGAGAAGATCCTGCAGTACCGGG  
 AGCTCACCAAGCTGAAGAGCACCTACATTGACCCCTGCCGGACCTCATCCACCC  
 10 CAGGACGGGCCGCCTCCACACCCGCTCAACCAGACGCCACGCCACGGCAG  
 GCTAAGTAGCTCGATCCCAACCTCCAGAACATCCCCGTCCGCACCCGCTTGGG  
 CAGAGGATCCGCCGGCCTTCATCGCCGAGGAGGGTGGCTATTGGTGGCCCTG  
 GACTATGCCAGATAGAGCTCAGGGTGCTGGCCCACCTCTCCGGCAGCAGAAC  
 CTGATCCGGGTCTCCAGGAGGGCGGGACATCCACACGGAGACGCCAGCTGG  
 ATGTTCGCGTCCCCGGAGGCCGTGGACCCCTGATGCCCGGGCGGCCAAG  
 15 ACCATCAACTCGGGGTCTCTACGGCATGTCGGCCCACCGCCTCTCCAGGAGC  
 TAGCCATCCCTTACGAGGAGGCCAGGCCTTCATTGAGCGCTACTTCAGAGCTT  
 CCCCAAGGTGCCGGCTGGATTGAGAACCCCTGGAGGAGGGCAGGAGGCCGG  
 GGTACGTGGAGACCCCTTCAGGCCGCCGCTACGTGCCAGACCTAGAGGCC  
 GGGTGAAGAGCGTGGAGGCCGGAGGCCGAGCGCATGGCCTCAACATGCCGTCC  
 20 AGGGCACCGCCGCCACCTCATGAAGCTGGCTATGGTAAGCTCTCCCCAGGCT  
 GGAGGAAATGGGGCCAGGATGCTCCTCAGGTCCACGACGAGCTGGCCTCGA  
 GGCCCCAAAAGAGAGGGCGGAGGCCGTGGCCGGCTGGCCAAGGAGGTATGG  
 AGGGGGTGTATCCCCCTGGCCGTGCCCTGGAGGTGGAGGTGGGATAGGGAGG  
 ACTGGCTCTCCGCCAAGGAGGGCATTGATGCCCGGGAGGCCATCATC  
 25 ATCATCATCATTAA

**SEQ ID NO:12 The amino acid sequence of PL- $\Delta$ Taq fusion protein**

MITNSKKKKKKRKKKKKKGGVTSGATVKFKYKGEKEVDISKIKKVWRVGK  
 MISFTYDEGGGKTGRGAVSEKDAPKELLQMLEKQKKGGVTSPKALEEAPWPPPEG  
 30 AFVGTVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKDLSVL  
 ALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGGEWTEEAGERAALSERLFAN  
 LWGRLEGEERLLWLYREVERPLSAVLAHMEATGVRLDVAYLALSLEVAAEIIARLE  
 AEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIV

EKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTP  
LGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIHTETASWMF  
GVPREAVDPLMRRAAKTINFVLYGMSAHLRSQELAIPYEEAQAFIERYFQSFPKVR  
AWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAAD  
5 LMKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEEAVARLAKEVMEGVYPL  
AVPLEVEVGIGEDWLSAKEGIDGRGGGGHHHHHH

**SEQ ID NO:13 PRIMER L71F**

5'-CCTGCTCTGCCGCTTCACGC-3'

10

**SEQ ID NO:14 PRIMER L71R**

5'-GCACAGCGGCTGGCTGAGGA-3'

**SEQ ID NO:15 PRIMER L18015F**

15 5'-TGACGGAGGATAACGCCAGCAG-3'

**SEQ ID NO:16 PRIMER L23474R**

5'-GAAAGACGA TGGGTCGCTAACACGC-3'

20 **SEQ ID NO:17 PRIMER L18015F**

5'-TGACGGAGGATAAC GCCAGCAG-3'

**SEQ ID NO:18 PRIMER L29930R**

5'-GGGGTTGGAGGTCAATGGGTTTC-3'

25

**SEQ ID NO:19 PRIMER L30350F**

5'-CCTGCTCTGCCGCTTCACGC-3'

**SEQ ID NO:20 PRIMER L35121R**

30 5'-CACATGGTACAGCAAGCCTGGC-3'

**SEQ ID NO:21 PRIMER L2089F**

5'-CCCGTATCTGCTGGGA TACTGGC-3

**SEQ ID NO: 22 PRIMER L7112R**

5'-CAGCGGTGCTGACTGAATCATGG-3'

**SEQ ID NO:23 PRIMER L30350F**

5 5'-CCTGCCTGCCGCTTCACGC-3'

**SEQ ID NO:24 PRIMER L40547R**

5'-CCAATACCCGTTCA TCGCGGC-3'

10 **SEQ ID NO:25 PRIMER H-Amelo-Y**

5'-CCACCTCATCCTGG GCACC-3'

**SEQ ID NO:26 PRIMER H-Amelo-YR**

5'-GCTTGAGGCCAACCATCAGAGC-3'

15

**SEQ ID NO:27 Human beta-globin primer 536F**

5'-GGTTGGCCAATCTACTCCCAGG-3'

**SEQ ID NO:28 Human beta-globin primer 536R**

20 5'-GCTCACTCAGTGTGGCAAAG-3'

**SEQ ID NO:29 Human beta-globin primer 1408R**

5'-GATTAGCAAAAGGGCCTAGCTTGG-3'

25

**WHAT IS CLAIMED IS:**

1. A protein consisting of at least two heterologous domains wherein a first domain that is a sequence-non-specific double-stranded nucleic-acid-binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain having a processive nature, where the presence of the sequence-non-specific double-stranded nucleic-acid-binding domain enhances the processive nature of the nucleic-acid-modifying domain compared to an identical protein not having a sequence-non-specific nucleic-acid-binding domain joined thereto.
2. A protein of claim 1 wherein the nucleic-acid-modifying domain has polymerase activity.
3. A protein of claim 1 wherein the nucleic-acid-modifying domain has thermally stable polymerase activity.
4. A protein of claim 1 wherein the nucleic-acid-modifying domain comprises a *Thermus* polymerase domain.
5. A protein of claim 1 wherein the nucleic-acid modifying domain comprises a *Pyrococcus* polymerase domain.
6. A protein of claim 1 wherein the nucleic-acid-modifying domain has RNA polymerase, reverse transcriptase, methylase, 3' or 5' exonuclease, gyrase, or topoisomerase activity.
7. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either Sac7d or Sso7d.
8. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain contains a 50 amino acid subsequence containing 50% amino acid similarity to Sso7d.

9. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against Sso7d.

10. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain is Sso7d.

11. A protein of claim 10 wherein the the nucleic-acid modifying domain comprises a *Pyrococcus* polymerase domain

12. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against the PCNA homolog of *Pyrococcus furiosus*.

13. A protein of claim 1 wherein the sequence-non-specific nucleic-acid-binding domain is the PCNA homolog of *Pyrococcus furiosus*.

14. A protein consisting of at least two heterologous domains, wherein a first domain that is a sequence-non-specific double-stranded nucleic-acid-binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain, where the presence of the sequence-non-specific nucleic-acid-binding domain stabilizes the double-stranded conformation of a nucleic acid by at least 1°C compared to an identical protein not having a sequence-non-specific nucleic acid-binding domain joined thereto.

15. A protein of claim 14 wherein the nucleic-acid-modifying domain has polymerase activity.

16. A protein of claim 14 wherein the nucleic-acid-modifying domain has thermally stable polymerase activity.

17. A protein of claim 14 wherein the nucleic-acid-modifying domain has an RNA polymerase, a reverse transcriptase, a methylase, a 3' or 5' exonuclease, a gyrase, or a topoisomerase activity.

18. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either Sac7d or Sso7d.

19. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain contains a 50 amino acid subsequence containing 50% amino acid similarity to Sso7d.

20. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against Sso7d.

21. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain is Sso7d.

22. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against the PCNA homolog of *Pyrococcus furiosus*.

23. A protein of claim 14 wherein the sequence-non-specific nucleic-acid-binding domain is the PCNA homolog of *Pyrococcus furiosus*.

24. A method of modifying a nucleic acid in an aqueous solution by:

(i) contacting the nucleic acid with a protein comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a catalytic nucleic-acid-modifying domain having a processive nature, where the sequence non-specific nucleic-acid-binding domain:

a. binds to double-stranded nucleic acid, and

b. enhances the processivity of the enzyme compared to an identical enzyme not having the sequence non-specific nucleic-acid-binding domain fused to it, and

wherein the solution is at a temperature and of a composition that permits the binding domain to bind to the nucleic acid and the enzyme to function in a catalytic manner, and

(ii) permitting the catalytic domain to modify the nucleic acid in the solution.

25. A method of claim 24 wherein the nucleic-acid-modifying domain has polymerase activity.

26. A method of claim 24 wherein the nucleic-acid-modifying domain has thermally stable polymerase activity.

27. A method of claim 26 wherein the nucleic-acid-modifying domain comprises a *Thermus* polymerase domain.

28. A method of claim 26 wherein the nucleic-acid-modifying domain comprises a *Pyrococcus* polymerase domain.

29. A method of claim 24 wherein the nucleic-acid-modifying enzyme has an RNA polymerase, a reverse transcriptase, a methylase, an exonuclease, a gyrase, a topoisomerase, or other processive enzyme activity that interacts with nucleic acid.

30. A method of claim 24 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either Sac7d or Sso7d.

31. A method of claim 24 wherein the sequence-non-specific nucleic-acid-binding domain contains a 50 amino acid subsequence containing 50% amino acid similarity to Sso7D.

32. A method of claim 24 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against Sso7d.

33. A method of claim 24 wherein the sequence-non-specific nucleic-acid-binding domain is Sso7d.

34. A method of modifying a nucleic acid by:

(i) contacting the nucleic acid with an aqueous solution containing a protein having at least two heterologous domains, wherein a first domain that is a sequence-non-specific double-stranded nucleic acid-binding domain is joined to a second domain that is a

catalytic nucleic-acid-modifying domain, where the presence of the sequence-non-specific nucleic-acid-binding domain stabilizes the double-stranded conformation of a nucleic acid by at least 1°C compared to an otherwise identical protein not having the sequence-non-specific nucleic-acid-binding domain joined to it; and, wherein the solution is at a temperature and of a composition that permits the binding domain to bind to the nucleic acid and the enzyme to function in a catalytic manner; and,

(ii) permitting the catalytic domain to modify the nucleic acid in the solution.

35. A method of claim 34 wherein the nucleic-acid-modifying domain has polymerase activity.

36. A method of claim 34 wherein the nucleic-acid-modifying domain has thermally stable polymerase activity.

37. A method of claim 36 wherein the nucleic-acid-modifying domain comprises a *Thermus* polymerase domain.

38. A method of claim 34 wherein the nucleic-acid-modifying enzyme has an RNA polymerase, a reverse transcriptase, a methylase, a exonuclease, a gyrase, or a topoisomerase activity.

39. A method of claim 34 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against either Sac7d or Sso7d.

40. A method of claim 34 wherein the sequence-non-specific nucleic-acid-binding domain contains a 50 amino acid subsequence containing 50% amino acid similarity to Sso7D.

41. A method of claim 34 wherein the sequence-non-specific nucleic-acid-binding domain contains a 50 amino acid subsequence containing 75% amino acid similarity to Sso7D.

42. A method of claim 34 wherein the sequence-non-specific nucleic-acid-binding domain specifically binds to polyclonal antibodies generated against Sso7d.

43. A method of claim 34 wherein the sequence-non-specific nucleic-acid-binding domain is Sso7d.

44. A method of amplifying a subsequence of a target nucleic acid using a polymerase chain reaction, the method comprising:

(i) contacting the target nucleic acid in an aqueous solution with a protein of claim 1 or claim 14, wherein the aqueous solution is of a composition that permits the binding domain to bind to the target nucleic acid and the polymerase domain to extend a primer that is hybridized to the target nucleic acid sequence;

(ii) incubating the solution using a polymerase chain reaction temperature profile that amplifies the subsequence.






Figure 2. PCR amplification with a 12 nt forward primer





Figure 3. Pfu-Sso7d is more efficient than DyNAzyme EXT in long PCR.



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/17492

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/12; C12Q 1/68, 1/48; C12P 19/34; C07K 14/00, 1/00  
 US CL : 435/194, 6, 15, 91.1; 530/300, 324, 350

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/194, 6, 15, 91.1; 530/300, 324, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,972,603 A (BEDFORD et al) 26 October 1999 (26.10.1999), see entire document.	1-44
Y.	BEDFORD et al.; The thioredoxin binding domain of bacteriophage T7DNA polymerase confers processivity on Escherichia coli DNA polymerase I. Proc. Natl. Acad. Sci. USA. January 1997, Vol. 94, pages 479-484, see entire document.	1-44
Y	LIM et al. The Mitochondrial p55 Accessory Subunit of Human DNA Polymerase g Enhances DNA Binding, Promotes Processive DNA Synthesis, and Confers N-Ethylmaleimide Resistance. J. Biological Chemistry. 31 December 1999, Vol. 274, No. 53, pages 38197-38203, see entire document.	1-44
Y, P	US 6,228,628 B1 (GELFAND et al) 08 May 2001 (08.05.2001) see entire document.	1-44

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 August 2001 (02.08.2001)

Date of mailing of the international search report

24 AUG 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Richard Hutson

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/17492

**Continuation of B. FIELDS SEARCHED Item 3:**

EAST, MEDLINE, BIOSIS, CAPLUS, EMBASE, JAPIO, PATOSEP, PATOSWO, SCISEARCH  
search terms: polymerase, sequence non-specific, dna binding domain, catalytic domain, fusion, hybrid, chimera processivity, Sac7d, Sso 7d, PCNA